Cumulated Subject Index
Vol.3, No.1-6; Vol.4, No.1-6, 1972

A

Abscess, perianal and ischiorectal
  management of *4:* 79
Acetazolamide
  grand mal
    dosage and desirable plasma levels *4:* 262
  half-life, plasma *4:* 245, 251
  mode of action *4:* 239–240, 243
  pharmacokinetic properties *4:* 245, 250–251
Acetohexamide
  dosage *3:* 100
  excretion *3:* 101
  half-life *3:* 100, 102
  hypoglycaemic activity characteristics *3:* 100, 102
  metabolism *3:* 101
  metabolites *3:* 101
  mode of action *3:* 89
  pharmacokinetics *3:* 100–102
  structure *3:* 99
Acetophenazine
  dosage relationships *4:* 339
  structural formula *4:* 328
Acetylcholine
  neurotransmission *4:* 53
Acetylcholine release
  pancuronium effect on *4:* 191
N-acetyl-cysteine
  compared with
    2-mercaptoethane sulphate *3:* 127–128
Acetylsalicylic acid
  see aspirin
Acidorrhoea, faecal
  lactulose *4:* 34–37, 40–41
Acidosis, lactic
  biguanides *3:* 92
Acromegaly
  chlorpromazine *4:* 303–304
  medroxyprogesterone *4:* 303
ACTH
  seizures, minor motor *4:* 264–265
    dosage and desirable plasma levels *4:* 262
Actinomycin D
  mode of action *3:* 235
  pharmacokinetic properties *3:* 234
  Wilms' tumour *3:* 346
Actinospectacin
  see spectinomycin
Adolescent girls
  drug taking: factors associated with progression to narcotic use *3:* 271
Adrenal cortex
  lithium effect on *3:* 456–457
Adrenal corticosteroid excess
  carbenoxolone sodium *3:* 386–388
Adrenaline
  structural formula *4:* 55
Adrenergic neurone blocking drugs
  hypertension *4:* 94, 98
α-Adrenergic receptor blocking drugs
  hypertension *4:* 94, 98
β-Adrenergic receptor blocking drugs
  hypertension *4:* 94, 98–99
  Parkinsonism *4:* 70
Adrenolytic activity
  pizotifen *3:* 188–189
Age
  antibacterial agents host determinant *4:* 142
  drug metabolism: effect on *3:* 295
Agranulocytosis
  phenothiazine derivatives *4:* 346
Alcohol
  withdrawal reactions *4:* 405
Alcoholism
  general problem *4:* 403–404
Alcoholism, acute *4:* 404
Alcoholism, chronic *4:* 404–405

Alcohols
chloral hydrate *qv*
triclofos *qv*
Alcuronium
cardiovascular effects
compared with
pancuronium *4:* 186
dose-response curve *4:* 197
duration of action
compared with
pancuronium *4:* 187
onset of action
compared with
pancuronium *4:* 183
potency in conscious subjects
compared with
pancuronium *4:* 196
d-tubocurarine *4:* 196
Aldosterone excretion
contraceptives, oral *3:* 111
Allergic rhinitis, seasonal
disodium cromoglycate *3:* 127
Allergy
antipsychotic drugs *4:* 346
cephalexin *3:* 66–68
Alkalinisation
erythromycin urinary activity enchanced *3:* 294
Alkylating agents *3:* 233–237
carcinogenic activity *3:* 362
cytological effects *3:* 236
Hodgkin's disease *3:* 341–343
mode of action *3:* 235
molecular effects *3:* 236–237
myelofibrosis *3:* 344
pharmacokinetics *3:* 235–236
seminoma *3:* 345
Alopecia
cytotoxic drugs *3:* 357–358
Aloxiprin
dosage
rheumatoid arthritis *3:* 130
Amantadine
adverse reactions *4:* 69
biological half-life *3:* 436
overdosage causing acute toxic psychosis *3:* 436
Parkinsonism *4:* 68–69
pharmacology *4:* 61
AMCA
see tranexamic acid
Amiloride
hypertension control *4:* 94–96
7-Aminocephalosporanic acid
structural formula *3:* 3
Aminoglycosides
in renal failure *3:* 264
Aminomethyl cyclohexane carboxylic acid
see tranexamic acid
7-(α-Amino-phenylacetamido)-
3-methyl-3-cephem-4-carboxylic acid
see cephalexin
Aminopyrine
interaction with
phenobarbitone *4:* 278
Aminorex
adverse reactions *4:* 301–302
pulmonary hypertension *4:* 301–302
Amitriptyline
adverse reactions *4:* 384–385
in asthma *4:* 309–310
dosage guide *4:* 378
structural formula *4:* 366
toxic doses *4:* 384–385
Ammonia
intoxication
congenital disorders of
lactulose *4:* 28
metabolism, cerebral
lactulose *4:* 37
tolerance studies *4:* 37–39
transport: colonic
lactulose *4:* 34–37
Amphetamine
Parkinsonism *4:* 69–70
Ampicillin
acute upper respiratory tract infection complicated by
bacterial otitis media *3:* 6
adverse reactions *3:* 30, 31, 438
antibacterial activity *in vitro 3:* 317
bronchitis, chronic, acute excerbations of *3:* 6
bronchitis, purulent *3:* 6
cross-resistance
cephalexin *3:* 51–52
dosage
urinary tract infections *3:* 30
protein binding *3:* 58, 59
pyelonephritis *3:* 31
rashes in glandular fever *3:* 438
in renal failure *3:* 265
serum levels *3:* 54, 317
structural formula *3:* 4, 64, 316
urinary tract infections
compared with
cephalexin *3:* 29–32
failures *3:* 30
primary treatment *3:* 416
recurrence *3:* 30
see also penicillin derivatives
Ampicillin-probenecid
gonorrhoea: effective in males *3:* 292
Amylobarbitone
absorption *3:* 120
Amylobarbitone, sodium
grand mal status epilepticus *4:* 265
Anaemia, pernicious
cephalexin absorption *3:* 56
Anaesthesia
antihypertensives should not be withdrawn *3:* 266, 267
hypno-sedative drugs *3:* 118–119
pancuronium effect on *4:* 200
post-halothane jaundice *3:* 113–114
Anaesthetic agents
halothane
post-halothane jaundice *3:* 113–114
inhalational
forane *3:* 462–463

halothane *3:* 463–467
methoxyflurane *3:* 466–467
interactions with
pancuronium *4:* 191–192, 200–201
possible risks from chronic exposure *3:* 433–432
Anaesthetic, primary
influence on pancuronium dose *4:* 180
Anaesthetists
high miscarrage rates *3:* 433–434
Analgesic nephropathy
a review *4:* 124–125
Analgesia, postoperative
methotrimeprazine
compared with
pethidine *4:* 310–311
pethidine
compared with
methotrimeprazine *4:* 310–311
Analgesics
asthma *3:* 437
dysmorphology *3:* 110
methotrimeprazine *qv*
pethidine *qv*
response of aspirin-allergic patients to challenge by *3:* 437
Aneuryms, intracranial ruptured
antifibrinolytic agents management of *4:* 114
Angina
clofibrate *4:* 101–105
Angina, pre-infarction
diagnosis *4:* 284–285
Ano-rectal conditions
diagnosis of *4:* 75
management of *4:* 75–80
Anorexiants
chlorphentermine *qv*
diethylpropion *qv*
fenfluramine *qv*
phentermine *qv*
Antacids
absorbent capacity *3:* 378–379
dysmorphology *3:* 110
interactions *3:* 378–379
neutralising capacity *3:* 376
peptic ulcer *3:* 374–380
bowel function disturbance *3:* 377
complications of therapy *3:* 377–379
current status *3:* 379–380
hypercalcaemia *3:* 377
intestinal obstruction *3:* 379
milk alkali syndrome *3:* 377
pharmacological basis of therapy *3:* 375–376
phosphorus depletion syndrome *3:* 379
renal calculi *3:* 377–378
sodium toxicity *3:* 378
reflux oesophagitis *3:* 395
Antianxiety drugs
adverse reactions *4:* 399–400
chemical classes *4:* 389–391
choice of drug *4:* 395–396
clinical evaluation, problems *4:* 387–389
clinical use, principles of *4:* 396–399
complications *4:* 399–400
concomitant non-drug treatment *4:* 397
doses and dosage schedules *4:* 398–399
duration of treatment *4:* 397
efficacy *4:* 391–393
in anxiety *4:* 391–392
in depression *4:* 392
metapharmacological considerations *4:* 393
pharmacological properties *4:* 389, 391
special problems *4:* 361–410
structural formulae *4:* 390
use in medical practice *4:* 386
Antiarrhythmic activity
pizotifen *3:* 190–191
Antiarrhythmic agents
interaction with
non-depolarising skeletal muscle relaxants *4:* 214, 217
ventricular fibrillation complicating myocardial infarction: failure to control *3:* 281–282
Anti-arthritic drugs
gastric ulcer *3:* 442
Antibacterial agents
cephalexin *3:* 1–8, 9–78
cephaloglycin *3:* 4
cephaloridine *3:* 4
cephalothin *3:* 2–4
epicillin *qv*
half-lives *3:* 261–263
minocycline *qv*
otitis media, acute suppurative *3:* 419
penicillin *3:* 2
in renal failure *3:* 261–265
renal function, normal *3:* 262–263
spectinomycin *qv*
sulphanilamide *3:* 1–2
urinary tract infection
primary treatment *3:* 415–416
see also antibiotics
Antibacterial agents, systemic
adverse reactions *4:* 133, 140–141
bacteriological activity *4:* 136–137
causative organism of infection *4:* 132–133
clinical usefulness *4:* 136–137
drug interactions *4:* 144–145
a guide to selection of *4:* 132–145
host determinants of response *4:* 140–141
nature of illness to be treated *4:* 133
patient preference *4:* 133–135
therapeutic usefulness *4:* 138–139
Antibacterial eye drops
gonococcal ophthalmia neonatorum *3:* 291–292
Antibacterial spectrum
cephalexin *3:* 43–44
Antibiotics
antibacterial activity *3:* 314–330
diarrhoeas, acute infective *3:* 132
gastroenteritis *3:* 132
interaction with
non-depolarising skeletal muscle relaxants *4:* 213–214, 216
pharmacokinetics *3:* 314–330
prophylaxis in dental extraction *3:* 279

synergism against enterococci *3:* 133–134
therapeutic efficacy *3:* 314–330
see also antibacterial agents
Antibiotics, antineoplastic
cytological effects *3:* 238
molecular effects *3:* 238
pharmacokinetics *3:* 234, 237
Antibiotics, broad spectrum
cephalexin *qv*
cephalosporins *qv*
Antibradykinin activity
pizotifen *3:* 188
Anticholinergic activity
pizotifen *3:* 188
Anticholinergic drugs
clinical pharmacology *3:* 380–381
complications *3:* 384
contra-indications *3:* 382–384
dosage *3:* 381
Parkinsonism *4:* 68
duodenal ulcer *3:* 383
gastric ulcer *3:* 383
indications in peptic ulcer *3:* 382
irritable colon syndrome *3:* 396
Parkinsonism *4:* 67–68
peptic ulcer *3:* 380–384
pharmacology *4:* 61–62
therapeutic trials *3:* 381–382, 383
Anticholinesterase activity
pancuronium effect on *4:* 207–208
Anticholinesterases
interaction with
non-depolarising skeletal muscle relaxants *4:* 214
Anticonvulsant drugs
adverse reactions *4:* 265–270
after-discharges, effect on *4:* 239
cerebellar damage *4:* 270
clinical pharmacological and therapeutic aspects *4:* 256–282
coagulation defect *4:* 269
drug metabolism induction *4:* 271
drug metabolism inhibition *4:* 271–275
dysmorphogenicity *4:* 269–270
epilepsy: withdrawal of *3:* 454
folic acid deficiency *3:* 455–456
gastro-intestinal effects *4:* 268
half-lives, plasma *4:* 244–245
hypno-sedative drugs *3:* 118–119
idiosyncratic manifestations *4:* 268–269
interactions *4:* 270–280
intoxication
signs and symptoms *4:* 266–267
mode of action *4:* 237–246
paediatric doses *4:* 262
paramethadione *3:* 108–109
patho-physiological and pharmacological aspects *4:* 227–255
pentylenetetrazol stimulation, effect on *4:* 239
pharmacokinetic basis of interactions *4:* 270–275
pharmacokinetic properties *4:* 244–245, 246–251
in pregnancy *4:* 269–270
coagulation defect *4:* 269
seizure threshold, effect on *4:* 239
therapy, miscellaneous complications *4:* 268–269
trimethadione *3:* 108–109
Antidepressant activity
pizotifen *3:* 189–190
Antidepressant drugs
adverse reactions *4:* 383–386, 399–400
therapeutic doses *4:* 383–384
toxic doses *4:* 384–386
chemical properties *4:* 365–373
chemical structures *4:* 365–367
combinations *4:* 382–383
complications *4:* 383–386, 399-400
concomitant non-drug treatment *4:* 377
dosage guide *4:* 378
doses and dosage schedules *4:* 380–381
efficacy *4:* 373–375
maintenance therapy *4:* 382
no ideal *4:* 365
pharmacological basis *4:* 367–369
pharmacological properties *4:* 365–373
principles in use of *4:* 375–383
selection of *4:* 377–380
special problems *4:* 361–410
therapeutic doses
adverse reactions *4:* 383–384
toxic doses
adverse reactions *4:* 384–386
Antidepressant treatment
indications for use *4:* 375–377
Antidepressants, tricyclic
acute depressions *4:* 351
dosage guide *4:* 378, 398
pharmacokinetics *4:* 370–373
pharmacological properties *4:* 394
plasma levels *3:* 427
sedative activity *4:* 378
structural formulae *4:* 366
therapeutic effect *3:* 427
toxic doses *4:* 384–386
Antifibrinolytic agents
management of ruptured intracranial aneurysms *4:* 114
tranexamic acid *4:* 114
Antigen response
mechanism *2:* 231–232
Antihistamine activity
pizotifen *3:* 187
Antihistamines
Parkinsonism *4:* 69
Antihypertensive drugs
anaesthesia: no withdrawal necessary *3:* 266–267
hypertension *4:* 90–100
mode of action *4:* 94, 96–97
Antihypertensive therapy
stroke *3:* 452–453
Anti-insulin hormones *3:* 85
Antimanic drugs *4:* 347–357
mode of action possibilities *4:* 351–352
pharmacokinetics *4:* 352–353
pharmacological considerations *4:* 351–353
Antimetabolites
mode of action *3:* 235
pharmacokinetics *3:* 234, 243–246

Antimicrobial activity
cephalexin *3:* 43–52
Antimicrobial agents
cephalexin *3:* 1–8, 9–78
sulphanilamide *3:* 1–2
Antineoplastic drugs
adverse reactions *3:* 352–365
biochemical and clinical pharmacological considerations *3:* 227–253
dosage, suboptimum *3:* 355–356
overdosage *3:* 355
pharmacological considerations in use *3:* 232–233
therapeutic problems *3:* 352–365
therapeutic uses *3:* 331–351
Antiparkinsonian drugs
pharmacology *4:* 49–74
therapeutic aspects *4:* 49–74
Antipepsin agents
peptic ulcer *3:* 390
Antiproliferative drugs
see antineoplastic drugs
Antipsychotic drugs
adverse reactions *4:* 344–346
allergic manifestations *4:* 346
behavioural adverse reactions *4:* 345
chemical and pharmacological differences *4:* 326–333
combinations of drugs *4:* 342–343
complications of *4:* 344–346
concomitant non-drug therapy *4:* 343–344
dosage *4:* 338–341
pharmaceutical preparations *4:* 339
dosage guide *4:* 398
dosage relationships *4:* 339
general considerations *4:* 344–345
indications for use *4:* 334–336
maintenance treatment *4:* 341–342
miscellaneous complications *4:* 346
neurological adverse reactions *4:* 345–346
pharmacological properties, common *4:* 330–331
pharmacological screening tests *4:* 331
psychoses, functional *4:* 335–336
schizophrenia *4:* 334–335
toxic manifestations *4:* 346
use of: principles *4:* 336–344
no trivial indications *4:* 336–337
rational selection of drugs *4:* 337
Antiserotonin activity
pizotifen *3:* 186–187
Antiserotonin agents
cyproheptadine *qv*
methdilazine *qv*
methylergol carbamide maleate *qv*
methysergide *qv*
migraine: effect on *3:* 176–178, 185
Antithyroid drugs
predicting, the outcome of treatment *3:* 445–447
Anti-ulcer agents
peptic ulcer *3:* 373
Antivertiginous drugs
pharmacological properties *4:* 118–120
Anxiety
antianxiety drugs efficacy *4:* 391–392
measurement of *4:* 387
Apomorphine
Parkinsonism *4:* 69
Arabinosides
cytological effects *3:* 247–248
molecular effects *3:* 248
pharmacokinetics *3:* 247
Arrhythmia, cardiac
classification *4:* 285–286
Arrhythmias, ventricular
examples of *4:* 285–286
lignocaine *4:* 286–287
prevention of *4:* 286–287
procainamide *4:* 287
treatment of *4:* 286–287
Arteriosclerosis, cerebral
hypoglycaemic agents, oral *3:* 219
Artery disease, coronary
glyceryl trinitrate, diagnostic test *4:* 299–300
hypoglycaemic agents, oral *3:* 219
Arthritis, acute
interval treatment *3:* 425
management *3:* 424–426
practical problems *3:* 425–426
Arthritis, crystal
gout *3:* 423
Arthritis, rheumatoid
aloxiprin *3:* 130
azathioprine *3:* 129–131
cyclophosphamide *3:* 129–131
cytotoxic drugs *3:* 129–131
gastric ulcer *3:* 442
gold *3:* 285
plasma gold estimation in patients receiving chrysotherapy *3:* 429–430
renal disorders *4:* 125
L-Asparaginase
see colaspase
Aspirin
allergic patients response to challenge by some analgesics *3:* 437
dysmorphology *3:* 110
osteoarthritis *3:* 132
peptic ulcer *3:* 370–371
see also salicylates
Asthma
amitriptyline therapy *4:* 309–310
analgesics *3:* 437
exercise-induced
disodium cromoglycate effect on *3:* 126
fluorinated hydrocarbon blood levels after inhalation of pressurised aerosols *3:* 430
hyperventilation-induced
disodium cromoglycate effect on *3:* 126
Ataxia
phenytoin intoxication *4:* 260
ATP
adenosine triphosphate
Atrio ventricular block
example of *4:* 286
Atrophy, cerebral
folic acid concentrations in CSF *3:* 455–456
in marihuana smokers *3:* 268–269

Atropine
bradyarrhythmias *4:* 287
heart rate: effect on *3:* 432–433
heart rhythm: effect on *3:* 432–433
myocardial infarction *3:* 448
AV block
see atrioventricular block
Azathioprine
Crohn's disease *3:* 282
dosage
rheumatoid arthritis *3:* 129–130
glomerulonephritis, membranous or proliferative *3:* 283
pharmacokinetic properties *3:* 234
protein binding *3:* 234
rheumatoid arthritis *3:* 129–131
ulcerative colitis *4:* 304–305

B

Bacitracin
in renal failure *3:* 264
Back pain, low
aetiology and treatment *3:* 460–461
Bacterial endocarditis
see endocarditis, bacterial
Barbitone
absorption *3:* 120
dosage: hypnotic *3:* 121
metabolism *3:* 121
Barbiturates
amylobarbitone *qv*
butobarbitone *qv*
dosage guide *4:* 398
dysmorphology *3:* 110
excretion *3:* 122
interaction with
coumarin anticoagulants *3:* 121
griseofulvin *3:* 121
phenytoin *3:* 121
metabolism *3:* 120–121
overdosage *3:* 122
pentobarbitone *qv*
phenobarbitone *qv*
structural formulae *4:* 390
BC-105
see pizotifen
BCG
administration with tetanus toxoid and oral poliomyelitis vaccines *3:* 290–291
Benzodiazepines
chlordiazepoxide *qv*
dosage guide *4:* 398
diazepam *qv*
drug interactions *3:* 259–260
flurazepam *qv*
half-lives *4:* 395
medazepam *qv*
mode of action *4:* 243
nitrazepam *qv*
oxazepam *qv*
pharmacological properties *4:* 394
popularity *4:* 395–396
safety *3:* 122
structural formulae *4:* 390
Benzoquinolizine derivatives
tetrobenazine *qv*
Benzylpenicillin
adverse reactions *3:* 22
+ cephalexin
septicaemia *3:* 41
dosage
β-haemolytic streptococcal infections *3:* 22
β-haemolytic streptococcal infections *3:* 6
compared with
cephalexin *3:* 21–22
failures *3:* 22
recurrence *3:* 22
pneumococcal pneumonia *3:* 6
pneumonia *3:* 6
in renal failure *3:* 265
septicaemia *3:* 6
streptococcal pharyngitis *3:* 5
see also penicillin derivatives
Betahistine hydrochloride
vestibular function modification *4:* 120–121
Betamethasone-17-valerate
adverse reaction *3:* 438
Cushing's syndrome from percutaneous absorption of *3:* 438
Biguanides
acidosis, lactic *3:* 92
adverse reactions *3:* 221–222
blood lipids: effect on *3:* 93–94
body weight: effect on *3:* 93–94
buformin *qv*
fibrinolytic activity enhanced *3:* 94
hypoglycaemic activity characteristics *3:* 103
metformin *qv*
mode of action *3:* 91–93
aerobic glycolysis inhibition *3:* 92
glucose; absorption impaired *3:* 93
glucose, peripheral utilisation increased *3:* 92
specific enzyme inhibition *3:* 93
pharmacokinetics *3:* 103
phenformin *qv*
structure basis *3:* 103
Biliary tract infections
cephalexin *3:* 42
Bioavailability
drugs *4:* 296
erythromycins *3:* 431
Biogenic amines
migraine: role in *3:* 183
see also serotonin
Biopsy, gastric
peptic ulcer diagnosis *3:* 371–372
Blood-brain barrier
hypno-sedative drugs *3:* 118
Blood pressure
pancuronium
effect on *4:* 201–203
type of surgery *4:* 177
Blood pressure elevation
see hypertension
Blood pressure, high
see hypertension

Body weight
biguanides effect on *3:* 93–94
hypoglycaemic agents, oral effect on *3:* 93–94
Bradyarrhythmias
atropine *4:* 287
examples of *4:* 285–286
treatment of *4:* 287
Bradycardia, sinus
example of *4:* 286
Bradykinin
migraine: role in *3:* 155
Brain syndromes, organic
antipsychotic drugs *4:* 336
Breast milk
cephalexin *3:* 58
diazepam *4:* 250
phenobarbitone *4:* 248
phenytoin *4:* 248
Bronchial infections, purulent
cephalexin *3:* 17–19
bacteriological results *3:* 18
therapeutic results *3:* 18
Bronchiectasis
cephalexin *3:* 16–17
Bronchitis
hashish *4:* 428–429
Bronchitis, acute
cephalexin *3:* 15–19
Bronchitis, chronic
acute exacerbations of
drug of choice *3:* 6
antibacterial agents *4:* 138–139
atmospheric pollution *4:* 81
bronchodilator drugs *4:* 83
cephalexin *3:* 16–19
chemotherapy *4:* 82–83
chloramphenicol *4:* 82
cor pulmonale development *4:* 83
co-trimoxazole *4:* 82
lung function tests *4:* 84
management of *4:* 81–84
physiotherapy *4:* 83
polycythaemia development *4:* 84
smoking, relationship to *4:* 81
tetracyclines *4:* 82
Bronchitis, purulent
drug of choice *3:* 6
Bronchodilator drugs
chronic bronchitis *4:* 83
Bronchopneumonia
cephalexin *3:* 15–19
Burkitt's tumour
drugs of choice *3:* 346
treatment schedule *3:* 346
Busulphan
chronic granulocytic leukaemia *3:* 338–339, 354–355
dosage, suboptimum *3:* 356
mode of action *3:* 235
pharmacokinetics *3:* 234
pulmonary fibrosis *3:* 358
'Busulphan lung'
see busulphan: pulmonary fibrosis
Butabarbitone
dosage guide *4:* 398
structural formula *4:* 390
Butaperazine
dosage relationships *4:* 339
Butobarbitone
see butabarbitone
Butylbiguanide
see biguanides
Butyrophenone derivatives
haloperidol *qv*
trifluperidol *qv*

C

Calcitonin, human
Paget's disease of bone *3:* 444
Calcitonin M
see calcitonin, human
Calculi, renal
antacid therapy complication *3:* 377–378
Cancer, cutaneous
cytotoxic therapy *3:* 286
Cancer of the lip
cause and prevention *3:* 469–470
Cancer, skin
immunosuppression *4:* 123
Candidiasis
diagnosis *4:* 421–422
treatment *4:* 424
Cannabis
see marihuana
Carbamates
meprobamate *qv*
Carbamazepine
grand mal *4:* 264
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 245, 250
interaction with
phenytoin *4:* 278
warfarin *4:* 278
mode of action *4:* 239–241
pharmacokinetic properties *4:* 245, 250
Carbenicillin
in renal failure *3:* 264
Carbenoxolone sodium
adrenal corticosteroid excess *3:* 386–388
adverse reactions *3:* 385–388
clinical revelance *3:* 388
complications *3:* 386–388
Cushing's syndrome *3:* 387
dosage *3:* 385
duodenal ulcer *3:* 389
fluid retention *3:* 386
gastric ulcer *3:* 389
hypertension *3:* 386
hypokalaemia *3:* 386–387
myositis *3:* 387
peptic ulcer *3:* 384–390
pharmacology *3:* 384–385
reflux oesophagitis *3:* 395
therapeutic trials *3:* 388–389
Carbohydrate
diabetes mellitus dietary management *3:* 211

Carbohydrate metabolism *3:* 82–85
gluconeogenesis *3:* 83–84
glucuronic acid pathway *3:* 83
glycogenesis *3:* 83
glycogenolysis *3:* 83
glycolytic pathway *3:* 82
hexose monophosphate shunt *3:* 82
pathways *3:* 82–83
pizotifen effect *3:* 191
Carbon dioxide
intraocular pressure in glaucoma *3:* 467–468
Carbonic anhydrase inhibitors
acetazolamide *qv*
sulthiame *qv*
Carcinogenicity
alkylating agents *3:* 362
Carcinoma of the head
methotrexate *3:* 346
treatment schedule *3:* 346
Carcinoma of the neck
see carcinoma of the head
Carcinoma, ovarian
chlorambucil *3:* 345
thio-TEPA *3:* 345
treatment schedule *3:* 345
Cardiac arrest
treatment of *4:* 288
Cardiac glycosides
digoxin *qv*
Cardiac slowing
myocardial infarction: major problem in prehospital phase *3:* 448
Cardiotoxicity
daunorubicin *3:* 358
Cardiovascular disease
hypoglycaemic agents, oral *3:* 215–216, 219, 222–224
phenformin *3:* 222–224
tolbutamide *3:* 222–224
Cardiovascular effects
levodopa *4:* 60, 64
pancuronium *4:* 176–179, 186–187, 192–193, 201–205, 222
Cardiovascular haemodynamics
pizotifen effect on *3:* 190
Cardiovascular mortality
hypoglycaemic agents, oral *3:* 222–224
Caries
fluoride in vitamin drops prevents *3:* 278–279
Carphenazine
dosage relationships *4:* 339
structural formula *4:* 328
Catapres
see clonidine
Catecholamine blood levels
pancuronium effect on *4:* 207
Catecholamines
synthesis *4:* 55
Catechol-*O*-methyl transferase inhibitors
Parkinsonism *4:* 70
Caved–S
see liquorice, deglycyrrhizinated
Cell cycle, animal *3:* 230–231
Cell proliferation
biochemistry *3:* 229–231
DNA *3:* 229–231
function *3:* 229–231
RNA *3:* 229–231
Celontin
see methsuximide
Central nervous system
dopaminergic-cholinergic balance *4:* 54–56
neurotransmitters *4:* 53–56
pizotifen, sedative effects *3:* 189
Centrencephalic grand mal
see grand mal
Centrencephalic petit mal
see petit mal
Cephalexin
adverse reactions *3:* 22, 23, 24, 29, 31, 32, 36, 43, 65–69
pregnant patients *3:* 65
absorption *3:* 52–57
children *3:* 55–56
coeliac disease, malabsorption syndrome *3:* 56
effect of food *3:* 54–55
gastro-intestinal disorders *3:* 56
infants *3:* 55–56
pernicious anaemia *3:* 56
allergy *3:* 66–68
antibacterial activity *in vitro 3:* 45, 317
antibacterial spectrum *3:* 43–44
antibacterial therapy: place in *3:* 1–8
antimicrobial activity *3:* 43–52
antimicrobial activity *in vitro 3:* 43–48
antimicrobial activity *in vitro 3:* 48–50
bacteria sensitivity *in vitro 3:* 45
bacterial endocarditis *3:* 41–42
+ benzylpenicillin
septicaemia *3:* 41
biliary tract infections *3:* 42
blood levels *3:* 52–53, 54
effect of food *3:* 55
breast milk *3:* 58
bronchial infections, purulent *3:* 17–19
bacteriological results *3:* 18
therapeutic results *3:* 18
bronchiectasis *3:* 16–17
bronchitis, acute *3:* 15–19
bronchitis, chronic *3:* 16–19
bronchopneumonia *3:* 15–19
cerebrospinal fluid penetration *3:* 59
children *3:* 55–56
composition *3:* 64–65
concentration in pus *3:* 59
contra-indications *3:* 70
Coombs test, positive direct *3:* 68–69
cross-allergenicity with penicillins *3:* 67–68
cross-resistance
ampicillin *3:* 51–52
methicillin *3:* 51
other cephalosporins *3:* 51–52
penicillins *3:* 51–52
cystic fibrosis *3:* 42
dialysis *3:* 62
diphtheria, tonsillar *3:* 20, 21

distribution *3:* 58–59
dosage *3:* 70–73
adults *3:* 70
bacterial endocarditis *3:* 42
biliary tract infections *3:* 42
cystic fibrosis *3:* 42
gonorrhoea *3:* 37–39, 71
infants and children *3:* 71
lower respiratory tract infection *3:* 16–19
meningococcal carriers *3:* 42
osteomyelitis *3:* 40–41
paediatrics *3:* 34, 36
penicillin-resistant staphylococcal infections *3:* 43
renal failure *3:* 71–73
haemodialysis *3:* 73
septicaemia *3:* 41
skin and soft tissue infections *3:* 33, 34, 35
syphilis *3:* 37, 40
upper respiratory tract infections *3:* 19–23
urinary tract infections *3:* 24, 26, 27, 29, 30 31–32
venereal disease *3:* 37–40
dosage calculation
renal failure *3:* 72–73
dosage regimens, empirical
renal failure *3:* 71–72
drug interactions *3:* 69
duration of treatment *3:* 71
dysmorphology studies *3:* 64
efficacy against common pathogens
lower respiratory tract infections *3:* 16
upper respiratory tract infections *3:* 20
urinary tract infections *3:* 27
efficacy against experimentally-induced infections in mice *3:* 49
efficacy in skin and soft tissue infections *3:* 35
eosinophilia *3:* 24, 65
excretion *3:* 59–62
renal failure *3:* 61–62
renal function, normal *3:* 60–61
experimentally-induced staphylococcal infections *3:* 49–50
experimentally-induced streptococcal infections *3:* 50
gastro-intestinal disturbances *3:* 65
glomerular filtration *3:* 60–62
gonorrhoea *3:* 37–39, 71
failures *3:* 38
male and female *3:* 38–39
haemodialysis *3:* 62, 73
haemoglobin level fall *3:* 66
β-haemolytic streptococcal infections
compared with
benzylpenicillin *3:* 21–22
failures *3:* 22
recurrence *3:* 22
β-haemolytic streptococcal pharyngitis
compared with
cephaloglycin *3:* 22–23
half-life, serum *3:* 53, 56–57
neonates and infants *3:* 53
renal function, impaired *3:* 53
hypersensitivity reactions *3:* 66–68
indications for use *3:* 65
infants *3:* 55–56
milk feeding influence *3:* 56
inoculum size effect on MIC *3:* 47
inoculum size: influence on activity *3:* 44–48
intraocular penetration *3:* 58
laboratory test modifications *3:* 69–70
lower respiratory tract infections *3:* 15–19
bacteriological results *3:* 16
paediatrics *3:* 34
therapeutic results *3:* 16
lung abscess *3:* 16
lymphadenitis *3:* 36
media: influence on activity *3:* 44–48
meningococcal carriers *3:* 42
failure *3:* 42
metabolism *3:* 59–62
minimum bactericidal concentration *3:* 44–46
minimum inhibitory concentrations *3:* 44–46
miscellaneous infections *3:* 41–42
paediatrics *3:* 36
neutropenia, reversible *3:* 65
organisms not active against *3:* 44
osteomyelitis *3:* 40–41
compared with
cephalosporins *3:* 40
penicillin derivatives *3:* 40
failure *3:* 41
long-term treatment *3:* 41
penicillin-resistant *3:* 40–41
+ other antibacterial agents *3:* 48
otitis media *3:* 21
otitis media, acute *3:* 20
otitis media, chronic *3:* 20
paediatric use *3:* 34, 36
penicillin allergy *3:* 5, 66
penicillin cross-allergenicity *3:* 67–68
penicillin cross-immunogenicity *3:* 67–68
penicillin-resistant staphylococcal infections *3:* 42–43
peritoneal dialysis *3:* 62
pH: influence on activity *3:* 44–48
pharmacodynamic studies *3:* 62–64
pharmacokinetic studies *3:* 52–62
pharyngitis, acute *3:* 20
placental transfer *3:* 59
pneumonia *3:* 15–19
pregnancy
adverse reactions *3:* 65
+ probenecid
gonorrhoea *3:* 37–39, 71
precautions in use *3:* 70
protein binding *3:* 58, 59
pyelonephritis *3:* 29
in renal failure *3:* 264
calculation of actual dosage *3:* 72–73
empirical dosage regimens *3:* 71–72
resistance *3:* 51–52
rhinosinusitis, acute *3:* 20, 21
saliva levels *3:* 42
scarlet fever *3:* 21, 22
septicaemias *3:* 41
failures *3:* 41
serum: influence on activity *3:* 44–48

serum levels *3:* 42, 53–54, 55
children *3:* 55–56
effect of probenecid *3:* 55
infants *3:* 55–56
skin infections *3:* 33–34, 35
bacteriological results *3:* 35
clinical results *3:* 35
soft tissue infections *3:* 33–34, 35
bacteriological results *3:* 35
clinical results *3:* 35
streptococcal pharyngitis
compared with
cyclacillin *3:* 23–24
phenoxymethylpenicillin *3:* 23–24
failures *3:* 23–24
structural formula *3:* 3, 4, 64
superinfections *3:* 69
syphilis *3:* 37, 40
failures *3:* 40
therapeutic trials *3:* 14–43
tissue concentration *3:* 58
tonsillar infections, acute *3:* 20–21
tonsillitis, acute *3:* 21–22
tonsillitis, acute follicular *3:* 21
toxicology studies *3:* 62–64
transaminases, serum: rise in *3:* 65–66
tubular secretion *3:* 60–62
upper respiratory tract infections *3:* 19–24
bacteriological results *3:* 19–20
comparative trials *3:* 21–24
non-comparative trials *3:* 21
paediatrics *3:* 36
therapeutic results *3:* 19–20
urinary glucose: false-positive reactions *3:* 69
urinary levels
renal failure *3:* 61–62
renal function, normal *3:* 60–61
urinary protein: false readings possible *3:* 70
urinary tract infections
bacteriological results *3:* 25–27
clinical results *3:* 25–27
comparative trials *3:* 28–33
compared with
ampicillin *3:* 29–32
cephaloridine *3:* 31–32
other cephalosporins *3:* 28–29
sulphonamides *3:* 31–32
failures *3:* 30
follow-up results *3:* 25
non-comparative trials *3:* 24–27
paediatrics *3:* 36
recurrence *3:* 30
venereal disease *3:* 36–40
bacteriological results *3:* 37–40
clinical results *3:* 37–40

Cephaloglycin
adverse reactions *3:* 4–5, 23, 29
antibacterial activity *3:* 3
dosage
β-haemolytic streptococcal pharyngitis *3:* 22
urinary tract infections *3:* 29
efficacy against experimentally-induced infections in mice *3:* 49
β-haemolytic streptococcal pharyngitis
compared with
cephalexin *3:* 22–23
physical properties *3:* 4
serum levels *3:* 54
structural formula *3:* 3
urinary tract infections
compared with
cephalexin *3:* 28–29

Cephaloridine
adverse reactions *3:* 66
antibacterial activity *3:* 4
dosage
osteomyelitis *3:* 40
urinary tract infections *3:* 29, 32, 33
efficacy against experimentally-induced infections in mice *3:* 49
excretion *3:* 4
half-life, serum *3:* 57
renal failure *3:* 57
inoculum size: effect on MIC *3:* 48
nephrotoxicity *3:* 4
protein binding *3:* 58, 59
in renal failure *3:* 264
serum levels *3:* 54
structural formula *3:* 3
syphilis
pregnancy *3:* 40
urinary tract infections
compared with
cephalexin *3:* 28–29, 31–32
see also cephalosporins

Cephalosporin C
structural formula *3:* 3

Cephalosporins
antibacterial therapy: place in *3:* 1–8
cross-allergenicity with penicillin *3:* 67–68
cross-resistance with cephalexin *3:* 51–52
oral preparations *3:* 1–8
osteomyelitis
compared with
cephalexin *3:* 40
parenteral preparations *3:* 1–8
penicillin allergic patients *3:* 66
penicillin cross-allergenicity *3:* 67–68
penicillin cross-immunogenicity *3:* 67–68
in renal failure *3:* 264

Cephalothin
adverse reactions *3:* 66
antibacterial activity *3:* 2–4
dosage
osteomyelitis *3:* 40
urinary tract infections *3:* 29
efficacy against experimentally-induced infections in mice *3:* 49
excretion *3:* 3
half-life, serum *3:* 57
renal failure *3:* 57
inoculum size effect on MIC *3:* 48
protein binding *3:* 58, 59
in renal failure *3:* 264
serum levels *3:* 54

urinary tract infections
compared with
cephalexin *3:* 28–29
see also cephalosporins
Cephalothin, sodium
structural formula *3:* 3
see also cephalothin
Cepor
see cephalexin
Ceporex
see cephalexin
Ceporexine
see cephalexin
Cerebellar damage
anticonvulsant drugs *4:* 270
phenytoin *4:* 270
Cerebral atrophy
see atrophy, cerebral
Cerebrospinal fluid
cephalexin penetration *3:* 59
lithium concentration *4:* 352
Cerumol
composition *3:* 125
ear wax solvent efficacy *3:* 125
Chemotherapeutic agents
see antimicrobial agents ents
Chemotherapy
chronic bronchitis *4:* 82–83
Chenodeoxycholid acid
cholesterol gallstone dissolution *3:* 458–459
Children
acute phenothiazine intoxication *3:* 436
cephalexin
absorption *3:* 55–56
dosage *3:* 71
digoxin dosage *3:* 410
enuresis: management of *3:* 136
psychoses
diagnostic difficulties *4:* 400
psychotherapeutic drugs *4:* 400–402
Children, hyperkinetic
dextroamphetamine *4:* 401
Chloral hydrate
excretion *3:* 121–122
rational therapy *3:* 122
Chlorambucil
chronic lymphocytic leukaemia *3:* 339
Hodgkin's disease *3:* 341
lymphosarcoma *3:* 340
mode of action *3:* 235
ovarian carcinoma *3:* 345
pharmacokinetics *3:* 234
reticulum cell sarcoma *3:* 341
Chloramphenicol
antibacterial activity *in vitro 3:* 317
chronic bronchitis *4:* 82
interaction with
phenytoin *4:* 276
metabolism *4:* 396
phenytoin intoxication *3:* 259–260
structural formula *4:* 390, 396
Chloroquine
myopathy *4:* 126
2-Chloro, 1-1-2 trifluoroethyl difluoromethyl ether
see ethrane
1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
see forane
Chlorphentermine
obesity *4:* 415
Chlorpromazine
acromegaly *4:* 303–304
dosage relationships *4:* 339
excretion *4:* 333
half-life plasma *4:* 333
manic-depressive, psychosis, manic phase *4:* 349
metabolism: routes of *4:* 332–333
pharmacokinetics *4:* 331–333
protein binding *4:* 333
schizo-affective disorder, excited *4:* 351
schizophrenia
improved under altered dosage schedules *3:* 456
structural formula *4:* 326, 328
Chlorpropamide
absorption *3:* 101
adverse reactions *4:* 302
anaphylactic reaction *4:* 302
diabetes insipidus *3:* 94
dosage *3:* 100
excretion *3:* 101
half-life *3:* 100, 101
hypoglycaemic activity characteristics *3:* 100, 101
mode of action *3:* 89
pharmacokinetics *3:* 100–101
structure *3:* 99
Chlorprothixene
dosage relationships *4:* 339
structural formula *4:* 326
Chlortetracycline
antibacterial activity *3:* 321
encephalopathy, portal systemic
compared with
lactulose *4:* 21–23
Cholangiography
renal failure caused by media *3:* 116
Cholecystography
renal failure caused by media *3:* 116
Chorea
contraceptives, oral *3:* 439–440
Choriocarcinoma
methotrexate *3:* 346
treatment schedule *3:* 346
Chrysotherapy
rheumatoid arthritis: plasma gold estimation *3:* 429–430
Clinistix
diabetes mellitus urine testing *3:* 212
Clinitest
diabetes mellitus urine testing *3:* 212
Clofibrate
angina *4:* 101–105
ischaemic heart disease *4:* 101–105
myocardial infarction *4:* 101–105
Clonidine
hypertension *4:* 94, 97
Cloxacillin
in renal failure *3:* 265

CNS
see central nervous system
Coagulation defects
anticonvulsant drugs in pregnancy *4:* 269
Coagulation, disseminated intravascular
+ septicaemia
heparin *3:* 134
Coeliac disease
malabsorption syndrome
cephalexin absorption *3:* 56
Coeliac disease, childhood
diagnosis *3:* 458
dietary management *3:* 458
Colaspase
cytological effects *3:* 239
half-life, plasma *3:* 234
leukaemia, acute *3:* 335
mode of action *3:* 235
molecular effects *3:* 239
pancreatic damage *3:* 359
pharmacokinetics *3:* 234, 238–239
Colistin sulphomethate
in renal failure *3:* 264
Colitis, ulcerative
aetiology and epidemiology *3:* 276
azathioprine *4:* 304–305
management of *3:* 276–277
medical *3:* 276–277
surgical *3:* 277
prognosis and course *3:* 276
Compound 469
see forane
Condylomata, anal
podophyllin compound paint *4:* 79
Congenital abnormalities
see dysmorphology
Conjuntivitis, gonorrhoeal
treatment *3:* 291
Constipation
lactulose *4:* 29–31
dosage *4:* 46
mode of action *4:* 39–41
Contraceptives, hormonal steroid
see contraceptives, oral
Contraceptives, oral
adverse reactions *3:* 111–112, 439–440
aldosterone excretion increase *3:* 111
chorea *3:* 439–440
hypertension
mode of action *3:* 111–112
spironolactone control *3:* 111
renin activity increase *3:* 111–112
thromboembolism *4:* 300–301
vascular incidents *4:* 300–301
Contrast media
adverse reactions *3:* 116
Convulsive disorders
classification of *4:* 229–232
clinical-electrographic *4:* 229–232
drug responsiveness *4:* 232
phenomenological *4:* 229
drug treatment *4:* 258–266
intoxication *4:* 259
plasma levels unexpectedly high *4:* 258
plasma levels unexpectedly low *4:* 259
plasma levels, therapeutic *4:* 259–261
patho-physiology *4:* 232–237
Coombs test, positive direct
cephalexin *3:* 68–69
Cor pulmonale
development of in chronic bronchitis *4:* 83
Cori cycle
glucose source *3:* 84
Coronary artery disease
glyceryl trinitrate, diagnostic test *4:* 299–300
hypoglycaemic agents, oral *3:* 219
Coronary attack
see infarction, myocardial
Corticosteroid therapy, intralesional
psoriasis *4:* 88
Corticosteroid therapy, systemic
psoriasis *4:* 88
Corticosteroid therapy, topical
psoriasis *4:* 87
Corticosteroids
adverse reactions *4:* 126–127
cytological effects *3:* 242
hepatitis, active chronic *4:* 305–306
molecular effects *3:* 242
peptic ulcer *3:* 371
pharmacokinetics *3:* 234, 241–242
Corticosteroids, topical
percutaneous absorption *3:* 438
Co-trimoxazole
adverse reactions *4:* 128–129
associated leucopenia after renal transplantation *4:* 128–129
chronic bronchitis *4:* 82
in renal failure *3:* 264
typhoid fever in children *4:* 113–114
urinary tract infection
primary treatment *3:* 416
Coumarins
interaction with barbiturates *3:* 121
Crohn's disease
azathioprine *3:* 282
CSF
cerebrospinal fluid
Cushing's syndrome
betamethasone-17- valerate percutaneous absorption *3:* 438
carbenoxolone sodium *3:* 387
Cyclacillin
adverse reactions *3:* 24
eosinophilia *3:* 24
dosage
streptococcal pharyngitis *3:* 23
streptococcal pharyngitis
compared with cephalexin *3:* 22–23
failures *3:* 23–24
Cyclandelate
intraocular pressure in glaucoma *3:* 467–468
Cyclic ethers
paraldehyde *qv*
Cyclophosphamide
adverse reactions *3:* 129–130

dosage
myelomatosis *3:* 135
rheumatoid arthritis *3:* 129–131
half-life plasma *3:* 234
Hodgkin's disease *3:* 341
leukaemia, acute *3:* 335
mode of action *3:* 235
myelomatosis
compared with melphalan *3:* 135
nephrosis childhood
compared with
prednisone *3:* 468–469
pharmacokinetic properties *3:* 234
protein binding *3:* 234
rheumatoid arthritis *3:* 129–131
thrombocytopenic purpura, 'refractory' *3:* 288
Cyclospasmol
see cyclandelate
Cyproheptadine
adverse reactions *3:* 176
dosage: migraine *3:* 176
structural formula *3:* 195
Cystic fibrosis
see fibrosis, cystic
Cytarabine
half-life, plasma *3:* 234
mode of action *3:* 235
pharmacokinetic properties *3:* 234
Cytology, exfoliative
peptic ulcer diagnosis *3:* 372
Cytotoxic drugs
alopecia *3:* 357–358
cytotoxicity *3:* 353–355
dysmorphogenic effects *3:* 360–362
hepatotoxicity *3:* 359
infection *3:* 356–357
malignant tumours *3:* 362–363
mode of action *3:* 334
mucous membranes: effect on *3:* 358
mutagenic effects *3:* 360
nausea and vomiting *3:* 357
psoriasis *4:* 87–88
renal complications *3:* 357
reproduction: effect on *3:* 359–362
rheumatoid arthritis *3:* 129–131
skin reactions *3:* 358
sterility: effect on *3:* 359–360
see also antineoplastic agents
Cytotoxic therapy
cancer, cutaneous and pre-cancer *3:* 286
Cytotoxid
drug therapy, topical *3:* 347

D

Dactinomycin
see actinomycin D
Daunorubicin
cardiotoxicity *3:* 358
half-life, plasma *3:* 234
mode of action *3:* 235
pharmacokinetics *3:* 234
DDE
see pesticides, organochlorine
DDT
interaction with
phenobarbitone *4:* 278
phenytoin *4:* 272, 278
phenytoin metabolism: influence on *4:* 272
see also pesticides, organochlorine
Decarboxylase inhibitors
levodopa metabolism *4:* 60–61
Decarboxylase inhibitors, peripheral
Parkinsonism *4:* 70
Dehydration
pancuronium: precautions *4:* 220
Demethylchlortetracycline
antibacterial activity *3:* 321
Demethyltetracycline
excretion rate *3:* 323
Dental extraction
antibiotic prophylaxis for *3:* 279
Deoxyribonucleic acid
see DNA
Dependence, physical
hypno-sedative drugs *3:* 119
Depepsen
see SN263
Depression
antianxiety drugs efficacy *4:* 392
classification *4:* 364
antidepressants: principles in use of *4:* 379
indications for drug treatment *4:* 375–377
noradrenaline hypothesis *4:* 369–370
nosology of *4:* 363–364
selection of drugs *4:* 377–380
Depressions, acute
lithium *4:* 351
tricyclic antidepressants *4:* 351
Depression, childhood
psychotherapeutic drugs *4:* 400–401
Depressive profiles
examples of *4:* 364
Dermatological reactions
antibacterial agents *4:* 140–141
Deseril
see methysergide
Desipramine
dosage and plasma level correlation *4:* 371
dosage guide *4:* 378
protein binding *4:* 370
structural formula *4:* 366, 371
Desmethylimipramine
see desipramine
Dexacillin
see epicillin
Dexamphetamine
dysmorphology *3:* 110
Dextran 70
thrombosis in femoral neck fractures, prophylaxis
compared with dicoumarol *4:* 116–117
thrombosis: prevention after pelvic surgery *4:*
117–118
Dextroamphetamine
dosage guide *4:* 378
hyperkinetic children *4:* 401
structural formula *4:* 366

Diabetes insipidus
chlorpropamide *3:* 94
hypoglycaemic agents, oral *3:* 94
Diabetes mellitus
aetiology: current views *3:* 88
diagnosis *3:* 206–209
diet factors to be considered *3:* 211
emergency diets *3:* 212
special food products *3:* 212
failure to maintain control *3:* 218
glaucoma, open-angle *3:* 271–272
glucose tolerance tests *3:* 206–209
renal glycosuria *3:* 207–208
renal threshold raised *3:* 208
hypoglycaemic agents, oral *3:* 214–217
hypoglycaemic therapy, initiation of *3:* 213–217
insulin insufficiency *3:* 88
insulin preparations *3:* 94–98
insulin therapy *3:* 213–214
management *3:* 209–212, 213–217
dietary *3:* 210–212
in pregnancy *3:* 219
in pregnancy *3:* 219
response, assessment of *3:* 217
treatment flow chart *3:* 217
urine testing *3:* 212
Dialysis
cephalexin *3:* 62
see also haemodialysis
Dialysis, peritoneal
cephalexin *3:* 62
Diamox
see acetazolamide
Diarrhoea
enteropathogenic *Esch. coli*
neomycin therapy *4:* 306–307
lactulose *4:* 45
Diarrhoeas, acute infective
antibiotics *3:* 132
Diarrhoeal syndrome of infancy
treatment, oral and parenteral *3:* 293
Diazepam
absorption *3:* 120
breast milk *4:* 250
dosage guide *4:* 398
in epilepsy of childhood *3:* 453–454
grand mal
dosage and desirable plasma levels *4:* 262
status epilepticus *4:* 265
half-life, plasma *4:* 245, 250
interaction with phenytoin *4:* 276
metabolism *4:* 250, 396
mode of action *4:* 239–240, 243
petit mal status epilepticus *4:* 266
pharmacokinetic properties *4:* 245, 250
phenytoin intoxication *3:* 259–260
placental transfer *4:* 250
seizures, minor motor *4:* 265
dosage and desirable plasma levels *4:* 262
structural formula *4:* 390, 396
Diazepam, parenteral
rigidity management *3:* 123
spasticity management *3:* 123
Diazoxide
adverse reactions *4:* 298–299
in hypertension with renal failure *4:* 298–299
DIC
see coagulation, disseminated intravascular
1,1,-dichloro-2,2-bis(p-chloro-phenyl)ethylene
see DDE
Dichlorodiphenyltrichloroethane
see DDT
Dicloxacillin
see penicillin derivatives
Dicoumarol
interaction with
phenobarbitone *4:* 278
phenytoin *4:* 276, 278
thrombosis in femoral neck fractures, prophylaxis
compared with dextran 70 *4:* 116–117
Diet
coeliac disease of childhood management *3:* 458
diabetes mellitus, management of *3:* 210–212
peptic ulcer management *3:* 392
psoriasis: role in *4:* 89
Diethylpropion
obesity *4:* 414
Digitalis
dosage *3:* 257
calculations *3:* 406–409
elderly patients *3:* 259
a guide to safe and effective therapy *3:* 404–413
in hypokalaemia, drug-induced *3:* 259
hypothyroid patients *3:* 259
inotropic effect *3:* 405–406
intoxication *3:* 254–256
metabolism *3:* 257
in renal insufficiency *3:* 259
serum levels *3:* 257, 259
toxicity
evidence *3:* 411, 412
treatment of *3:* 412
use of *3:* 254–259
Digitoxin
absorption *3:* 258
excretion *3:* 258
half-life, serum *3:* 258
interaction with
phenytoin *4:* 278
pharmacokinetics *3:* 258
serum levels *3:* 255
Digoxin
absorption *3:* 258, 405
in patients with malabsorption syndrome *4:* 426–427
congestive heart failure: special difficulty *3:* 412
dosage
average loading *3:* 408
children *3:* 410
determination of loading dose *3:* 409
determination of maintenance dose *3:* 409
planning *3:* 407
electrolyte balance *3:* 405
excretion *3:* 258
geriatric patients *3:* 410
half-life, serum *3:* 258

initial digitalisation recommended procedure *3:* 407–408
intoxication *3:* 115
myocardial response, factors which alter *3:* 405
overdosage *3:* 115
pharmacokinetics *3:* 258
plasma levels *3:* 411
preparations *3:* 410–411
radioimmunoassay *3:* 115
renal function effect on concentrations *3:* 408
serum levels *3:* 115, 255
tissue levels, factors which alter *3:* 404–405
total body concentrations *3:* 406, 408
toxicity *3:* 406
non-cardiac manifestations *3:* 412
risk *3:* 405
toxicology studies *3:* 115
L-3,4-Dihydroxyphenylalanine
see levodopa
Dilantin
see phenytoin
Dilatation, anal
haemorrhoids and fissures *4:* 77–78
Dimethothiazine
migraine *3:* 201
Dimethylbiguanide
see metformin
Dinitropropylacetate
mode of action *4:* 246
Dioctyl ear capsules
composition *3:* 125
ear wax solvent efficacy *3:* 125
Diphenhydramine
dosage guide *4:* 398
structural formula *4:* 390
Diphenylhydantoin
see phenytoin
Diphenylmethane
pharmacological properties *4:* 394
see also diphenhydrame
hydroxyzine
Diphenylmethane antihistaminics
dosage guide *4:* 398
structural formulae *4:* 390
Diphosphonates
Paget's disease of bone *3:* 444–445
Diphtheria, tonsillar
cephalexin *3:* 20, 21
2β16β-Dipiperidino-5-α-androstane-3d,17 β-diol diacetate dimethobromide
see pancuronium
Diplococcus pneumoniae
cephalexin sensitivity *in vitro 3:* 45
Disaccharides
malabsorption syndromes *4:* 1–3
Disodium cromoglycate
allergic rhinitis, seasonal *3:* 127
asthma, exercise-induced: effect on *3:* 126
asthma, hyperventilation-induced: effect on *3:* 126
mode of action *3:* 126
Disodium etidronate
see diphosphonates
Disulfiram
interaction with
phenytoin *4:* 276
Diuretics
hypertension control *4:* 94–95
interaction with
non-depolarising skeletal muscle relaxants *4:* 215
DMI
see desipramine
DNA
cell proliferation *3:* 229–231
synthesis *3:* 230–231
L-Dopa
see levodopa
Dopamine
biosynthesis *4:* 55
metabolism *4:* 55, 58
structural formula *4:* 55
see also monoamines
Dopaminergic-cholinergic balance
central nervous system *4:* 54–56
Doxepin
dosage guide *4:* 398
structural formula *4:* 366, 390
Doxycycline
antibacterial activity *3:* 321
excretion rate *3:* 323
protein metabolism *4:* 429–430
in renal failure *3:* 265
DPA
see dinitropropylacetate
DPH
see phenytoin
Drug action
pharmacokinetic principles *4:* 155–157
Drug availability *4:* 296
Drug evaluation
antianxiety drugs *4:* 387–389
psychotherapeutic drugs *4:* 324–325
Drug interactions
anaesthetics *4:* 191–192, 200–201
antacids *3:* 378
antiarrhythmic agents *4:* 214, 217
antibacterial agents *4:* 144–145
antibiotics *4:* 213–214, 216
anticholinesterases *4:* 214
anticonvulsant drugs *4:* 270–280
benzodiazepines *3:* 259–260
cephalexin *3:* 69
diuretics, *4:* 215, 217
ganglion blocking agents *4:* 215
hypno-sedative drugs *3:* 121
hypoglycaemic agents, oral *3:* 224–225
lactulose and neomycin *4:* 4–6
levodopa *4:* 66
MAO inhibitors *4:* 384
minocycline *3:* 325
muscle relaxants, centrally acting *4:* 215–216
pancuronium *4:* 191–192, 200–201, 213–218
phenobarbitone *4:* 274–275
phenytoin *3:* 259–260; *4:* 271–279
pizotifen *3:* 198, 200
sulphonylureas *3:* 224–225

Drug metabolism
acetohexamide *3:* 101
anticonvulsant drug induction of *4:* 271
anticonvulsant drugs inhibition *4:* 271–275
barbiturates *3:* 121
chlordiazepoxide *4:* 396
chlorpromazine *4:* 332–333
diazepam *4:* 250, 396
digitalis *3:* 257
dopamine *4:* 55, 58
glibenclamide *3:* 102
hypno-sedative drugs *3:* 120–121
imipramine *4:* 370–372
lactulose *4:* 43
levodopa *4:* 57–60
pancuronium *4:* 209–210
paracetamol *3:* 117
phenformin *3:* 103; *4:* 247–248, 272
phenytoin induction *4:* 271
primidone *4:* 249
sex and age effect on *3:* 295
sulphonylureas *3:* 100
tolazamide *3:* 102
trimethadione *4:* 249
Drug overdosage
amantadine *3:* 436
antineoplastic drugs *3:* 355
narcotics *4:* 407
Drug poisoning
digoxin *3:* 115
lithium *4:* 353
narcotics *4:* 407
paracetamol *3:* 117–118
phenothiazine *3:* 436
Drug reactions, adverse
amantadine *4:* 69
aminorex *4:* 301–302
amitriptyline *4:* 384
ampicillin *3:* 30, 31, 438
antianxiety drugs *4:* 399–400
antibacterial agents *4:* 133–135
antibacterial agents, systemic *4:* 140–141
anticonvulsant drugs *4:* 266–270
antidepressant drugs *4:* 383–386, 399–400
antineoplastic drugs *3:* 352–365
antipsychotic drugs *4:* 344–346
benzylpenicillin *3:* 22
betamethasone-17-valerate *3:* 438
biguanides *3:* 221–222
carbenoxolone sodium *3:* 385–388
cephalexin *3:* 22, 23, 24, 29, 31, 32, 36, 43, 59–62, 65–69
cephaloglycin *3:* 4–5, 23, 29
cephaloridine *3:* 66
cephalothin *3:* 66
chlorpropamide *4:* 302
contraceptives, oral *3:* 111–112, 439–440; *4:* 300–301
corticosteroids *4:* 126–127
co-trimoxazole *4:* 128–129
cyclacillin *3:* 24
cyclophosphamide *3:* 129–130
cyproheptadine *3:* 176
diazoxide *4:* 298–299
epicillin *3:* 319
fluorescein, intravenous *4:* 127–128
fluphenazine *4:* 309
gastro-intestinal reactions *3:* 441–442
halothane *3:* 113–114, 463–467; *4:* 104–107
hypno-sedative drugs *3:* 122
hypoglycaemic agents, oral *3:* 220–222
imipramine *4:* 384–385
immunosuppressive drugs *3:* 352–365
insulin *3:* 220
lactulose *4:* 12, 17, 24, 29–31, 45
levodopa *4:* 63–65
lignocaine *4:* 287
lithium *4:* 355–357
MAO inhibitors *4:* 386
methdilazine *3:* 176
methotrexate *4:* 88
methoxyflurane *3:* 466–467
methysergide *3:* 176
minocycline *3:* 325
nitrofurantoin *3:* 112–113
pancuronium *4:* 189, 211–212
penicillin *3:* 286–287
phenoxymethylpenicillin *3:* 24
phenytoin *3:* 428; *4:* 267–268
pizotifen *3:* 176, 179–180, 196–198
prednisone *4:* 121–122
rifampicin *3:* 440
spectinomycin *3:* 328
sulphonylureas *3:* 220–221
tranylcypromine *4:* 386
d-tubocurarine *4:* 189
Drug trials
antianxiety drugs *4:* 387–389
experimental designs *4:* 388
methodological problems *3:* 284
psychotherapeutic drugs *4:* 325
Drugs
generic equivalence *4:* 295–297
Duodenal reflux gastritis
peptic ulcer *3:* 369–370
Duodenal ulcer
anticholinergic drugs *3:* 383
carbenoxolone sodium *3:* 389
glycopyrronium *3:* 383
l-hyoscyamine *3:* 383
poldine *3:* 383
propantheline *3:* 383
tricyclamol *3:* 383
see also peptic ulcer
Duphalac
see lactulose
Dyskinesia
levodopa *4:* 63–64
Dysmorphogenic drugs
analgesics *3:* 110
antacids *3:* 110
anticonvulsant drugs *4:* 269–270
aspirin *3:* 110
barbiturates *3:* 110
cytotoxic drugs *3:* 360-362
dexamphetamine *3:* 110

factors needed to establish this man? *3:* 434–435
lithium *4:* 357
paramethadione *3:* 108–109
phenytoin *4:* 269
thalidomide *3:* 108, 434–435
trimethadione *3:* 108–109
Dysmorphology
cephalexin *3:* 64
lactulose *4:* 42
pancuronium *4:* 195
prescribed medication in pregnancy *3:* 109–110
self medication in pregnancy *3:* 109–110
Dystrophy, nail
triamcinolone acetonide dermo-jet injection treatment *4:* 307

E

Ear, middle exudates
erythromycin concentration *4:* 297
Ear wax solvents
efficacy *3:* 125
EEG
hypsarrhythmia pattern *4:* 232
EHDP
see diphosphonates
Electroencephalogram
see EEG
Electrolytes
pancuronium: precautions *4:* 220
Embden myerhof pathway
see glycolytic pathway
Embolism, pulmonary
heparin *3:* 280
streptokinase *3:* 280
Encephalopathy
treatment regimens *4:* 16–24
Encephalopathy, acute episodes
glucose syrup as control *4:* 24–25
Encephalopathy, hepatic
pathogenesis *4:* 11–12
Encephalopathy, portal systemic
lactulose *4:* 11–28
compared with
chlortetracycline *4:* 21–23
neomycin *4:* 14–24
sorbitol *4:* 18–19
dosage *4:* 45–46
mode of action *4:* 33–39
Endocarditis, bacterial
cephalexin *3:* 41–42
Endocarditis, staphylococcal
see endocarditis, bacterial
Endocrine diseases
glucose tolerance tests *3:* 209
Endocrine system
levodopa: effect on *4:* 60
Enflurane
see ethrane
Enterococci
antibiotic synergism *3:* 133–134
Entonox
pain relief in hospitals *3:* 273–274
Enuresis
children
management of *3:* 136
management of *3:* 136
Enzymes
biguanides: specific inhibition *3:* 93
Eosinophilia
cephalexin *3:* 24, 65
cyclacillin *3:* 24
phenoxymethylpenicillin *3:* 24
Epanutin
see phenytoin
Epicillin
absorption *3:* 317
adverse reactions *3:* 319
antibacterial activity *3:* 315–317
antibacterial activity *in vitro 3:* 317
dosage *3:* 318, 319
excretion *3:* 317
gastroenteritis *3:* 318
genitourinary tract infections *3:* 318
gonorrhoea *3:* 318, 319
metabolism *3:* 317–318
pharmacokinetics *3:* 317–318
plasma half-life *3:* 317–318
protein binding *3:* 318
respiratory tract infections *3:* 318
resistance to *3:* 316–317
serum levels *3:* 317–318
skin and soft tissue infection *3:* 318
structural formula *3:* 316
therapeutic trials *3:* 318
Epilepsies, focal
drug treatment *4:* 261–264
Epilepsy
anticonvulsant drug withdrawal *3:* 454
control in pregnant patients *3:* 108–109
folic acid role in *3:* 455
paramethadione and dysmorphology *3:* 109
phenobarbitone serum concentrations *3:* 428
phenytoin serum concentrations *3:* 428
trimethadione and dysmorphology *3:* 109
see also convulsive disorders
Epilepsy, childhood
diazepam *3:* 453–454
Epilepticus, status
drug treatment *4:* 265–266
Epinephrine
see adrenaline
Ergotamine tartrate
migraine, acute attack *3:* 156
Erythrasma
and pruritus ani *4:* 107–108
Erythromycin
absorption after food *3:* 431
alkalinisation of urine enhances activity against Gram-negative pathogens *3:* 294
bioavailability *3:* 431
concentration in middle ear exudates *4:* 297
Erythromycin estolate
absorption after food *3:* 431
Erythromycin stearate
absorption after food *3:* 431

Escherichia coli
cephalexin sensitivity *in vitro 3:* 45–47
Estrogens
see oestrogens
Ethanol
interaction with
phenytoin *4:* 278
Ethosuximide
half-life, plasma *4:* 245, 249
mode of action *4:* 239, 243
petit mal *4:* 261
dosage and desirable plasma levels *4:* 262
pharmacokinetic properties *4:* 245, 249
Ethrane
influence on pancuronium dose *4:* 180
Ethrane + N_2O
operating conditions *4:* 173
Extrapyramidal disorders
pathogenesis *4:* 51–53

F

Failure, heart
isoprenaline *4:* 281
treatment *4:* 288
Failure, heart, congestive
digoxin difficulty *3:* 412
Failure, renal
aminoglycoside dosage *3:* 264
ampicillin dosage *3:* 265
antibacterial agents *3:* 261–265
bacitracin dosage *3:* 264
benzylpenicillin dosage *3:* 265
carbenicillin dosage *3:* 264
cephalexin
dosage *3:* 71–73, 264
excretion *3:* 61–62
half-life, serum *3:* 56–57
urinary levels *3:* 61–62
cephaloridine
dosage *3:* 264
half-life, serum *3:* 57
cephalosporin dosage *3:* 264
cephalothin
dosage *3:* 264
half-life, serum *3:* 57
chloramphenicol dosage *3:* 264
cholangiography: due to media *3:* 116
cholecystography: due to media *3:* 116
cloxacillin dosage *3:* 265
colistin sulphomethate dosage *3:* 264
contrast media *3:* 116
co-trimoxazole dosage *3:* 264
doxycycline dosage *3:* 265
fusidic acid dosage *3:* 265
gentamicin dosage *3:* 264
hexamine dosage *3:* 264
hypertension
diazoxide *4:* 298–299
kanamycin dosage *3:* 264
lincomycin dosage *3:* 264
macrolide dosage *3:* 265
methicillin dosage *3:* 264
nalidixic acid dosage *3:* 264
neomycin dosage *3:* 264
nitrofurantoin dosage *3:* 264
norobicin dosage *3:* 265
penicillin dosage *3:* 264–265
polymyxin B dosage *3:* 264
polypeptide dosage *3:* 264
rifamide dosage *3:* 265
rifampicin dosage *3:* 265
streptomycin dosage *3:* 264
sulphadimidine dosage *3:* 265
sulphafurazole dosage *3:* 264
sulphamethoxazole dosage *3:* 265
tetracycline dosage *3:* 264
tetracyclines *4:* 427–428
urography: due to media *3:* 116
vancomycin dosage *3:* 264
Fat
diabetes mellitus dietary management *3:* 211
Fat synthesis
glucose source *3:* 83–84
Fenfluramine
obesity *4:* 415–416
Fetal malformations
see dysmorphology
Fibrillation, ventricular
example of *4:* 286
myocardial infarction complication antiarrhythmic agents failure to control *3:* 281–282
Fibrinolytic activity
biguanide enhancement *3:* 94
Fibrosis, cystic
cephalexin *3:* 42
Fibrosis, pulmonary
busulphan *3:* 358
nitrofurantoin *3:* 113
Fissure, anal
management of *4:* 78
Fistula, perianal and ischiorectal
management of *4:* 79
Fluorescein, intravenous
adverse reactions *4:* 127–128
Fluoride
caries prevention *3:* 278–279
Fluorocarbon–11
see trichlorofluoromethane
Fluorouracil
keratoses, solar *3:* 286
5-Fluorouracil
mode of action *3:* 235
pharmacokinetics *3:* 234
Fluphenazine
adverse reactions *4:* 309
dosage relationships *4:* 339
high dosage treatment for nonchronic refractory patients *4:* 308–309
schizophrenia *4:* 308–309
maintenance therapy *4:* 340
structural formula *4:* 328
Folic acid
anticonvulsant therapy *3:* 455–456
epilepsy: role of *3:* 455
Folic acid antagonists
cytological effects *3:* 244

molecular effects *3:* 244
pharmacokinetics *3:* 243–244
Food
insulin induction of storage *3:* 85
storage: insulin induced *3:* 85
Forane
influence on pancuronium dose *4:* 180
a new inhalational anaesthetic *3:* 462–463
physical properties *3:* 462
Forane + N_2O
operating conditions *4:* 173
Freon–11
see trichlorofluoromethane
Function, renal
digoxin concentrations *3:* 408
Fundal inspection
mydriatic drugs *3:* 468
Fusidic acid
in renal failure *3:* 265

G

Gallamine
cardiovascular effects
compared with
pancuronium *4:* 186
onset of action
compared with
pancuronium *4:* 183
Gallamine triethiodide
see gallamine
Gallstones, cholesterol
chenodeoxycholid acid dissolution *3:* 458–459
pathogenesis *3:* 459
prestone: is therapy safe? *3:* 459
Ganglion blocking activity
pancuronium *4:* 190
Ganglion blocking drugs
hypertension *4:* 94, 97
interaction with
non-depolarising skeletal muscle relaxants *4:* 215
Gardenal
see phenobarbitone
Gastric disease, organic
diagnosis *3:* 371–372
Gastric mucosa
salicylate effects on as seen by camera *3:* 443
Gastric secretion
peptic ulcer diagnosis *3:* 372
Gastric ulcer
anti-arthritic drugs *3:* 442
anticholinergic drugs *3:* 383
deglycyrrhizinated liquorice *3:* 389–390
glycopyrronium *3:* 383
rheumatoid arthritis *3:* 442
see also peptic ulcer
Gastric ulcer, chronic
carbenoxolone sodium *3:* 389
Gastro-camera
effects of salicylates on gastric mucosa revealed *3:* 443
Gastroenteritis
antibiotics *3:* 132
epicillin *3:* 318
Gastro-intestinal disorder
cephalexin absorption *3:* 56
Gastro-intestinal disturbances
cephalexin *3:* 65
Gastro-intestinal reactions
antibacterial agents *4:* 140–141
anticonvulsant drugs *4:* 268
of drugs *3:* 441–442
levodopa *4:* 63–64
Generic equivalence *4:* 295–297
Gentamicin
in renal failure *3:* 264
Genitourinary tract infections
epicillin *3:* 318
Geriatrics
digoxin *3:* 410
Glandular fever
ampicillin rashes *3:* 438
Glaucoma
anticholinergics contra-indicated *3:* 382, 384
chamber depth *3:* 467–468
intraocular pressure *3:* 467–468
vasodilators, systemic *3:* 467–468
Glaucoma, open-angle
diabetes mellitus *3:* 271–272
Glibenclamide
absorption *3:* 102
dosage *3:* 100
excretion *3:* 102
half-life *3:* 100, 102
hypoglycaemic activity characteristics *3:* 100, 102
metabolism *3:* 102
mode of action *3:* 89
pharmacokinetics *3:* 100, 102–103
structure *3:* 99
Glomerular filtration
cephalexin *3:* 60–62
Glomerulonephritis
azathioprine, value in *3:* 283
prednisone, value in *3:* 283
Glucathione
insulin degradation dependent on *3:* 87
Gluconeogenesis *3:* 83–84
enzymes *3:* 84
pathways *3:* 84
role in liver *3:* 83–84
Gluconeogenic enzymes *3:* 84
Glucose
biguanides impair absorption *3:* 93
biguanides: increase in peripheral utilisation *3:* 92
insulin secretion: effect on *3:* 86
phenformin peripheral utilisation increased *3:* 92
sources
glycerol *3:* 84
protein *3:* 84
via cori cycle *3:* 84
storage as fatty acids *3:* 83–84
storage as glycogen *3:* 83
Glucose, hepatic
sulphonylureas inhibit release *3:* 90
tolbutamide inhibits release *3:* 90
Glucose metabolism
see carbohydrate metabolism

Glucose syrup
encephalopathy, acute episodes, control of *4:* 24–25
Glucose tolerance
see carbohydrate metabolism
Glucose tolerance test
diabetes mellitus *3:* 206–207
diet *3:* 209
drug interference *3:* 209
endocrine diseases *3:* 209
factors influencing *3:* 209
obesity *3:* 209
pregnancy *3:* 207, 209
Glucose, urinary
cephalexin: false-positive reactions *3:* 69
Glucose-6-phosphate
metabolism
see carbohydrate metabolism
oxidation *3:* 82
Glucuronic acid pathway *3:* 83
Glycerol
cerebral oedema due to acute cerebral infarction *4:* 431–432
glucose source *3:* 84
Glycerol derivatives
dosage guide *4:* 398
structural formulae *4:* 390
Glyceryl trinitrate
diagnostic test for coronary artery disease *4:* 299–300
Glycodiazine
see glymidine
Glycogen
glucose reservoir *3:* 83
Glycogen synthesis
insulin *3:* 85
Glycogenesis *3:* 83
Glycogenolysis *3:* 83
Glycolysis, aerobic
biguanide inhibition *3:* 92
phenformin inhibition *3:* 92
Glycolytic pathway
carbohydrate metabolism *3:* 82
Glycopyrronium
duodenal ulcer *3:* 383
gastric ulcer *3:* 383
Glycosuria, renal
diabetes mellitus *3:* 207–208
Glymidine
dosage *3:* 100
half-life *3:* 100, 103
hypoglycaemic activity characteristics *3:* 100, 103
pharmacokinetics *3:* 100, 103
structure *3:* 99
Goekerman regimen, modified
psoriasis *4:* 87
Gold
rheumatoid arthritis *3:* 285
Gold, plasma
estimation in patients receiving chrysotherapy for rheumatoid arthritis *3:* 429–430
Gonococcal ophthalmia neonatorum
antibacterial eye drops *3:* 291–292
Gonorrhoea
ampicillin-probenecid *3:* 292
antibacterial agents *4:* 138–139
cephalexin *3:* 37–39, 71
failures *3:* 38
male and female *3:* 38–39
+ probenecid *3:* 37–39, 71
epicillin *3:* 318, 319
female
cephalexin *3:* 38–39
male
cephalexin *3:* 38–39
minocycline *3:* 324
probenecid + cephalexin *3:* 71
spectinomycin *3:* 326–328
Gonorrhoeal conjunctivitis
see conjunctivitis, gonorrhoeal
Gout
crystal arthritis *3:* 423
diagnosis *3:* 423–424
management of *3:* 422–426
urate pool *3:* 422–423
Grand mal
acetazolamide
dosage and desirable plasma levels *4:* 262
carbamazepine *4:* 264
dosage and desirable plasma levels *4:* 262
diazepam
dosage and desirable plasma levels *4:* 262
drug treatment *4:* 261–264
drugs of choice *4:* 263
generalised polyspike activity *4:* 230
methoin
dosage and desirable plasma levels *4:* 262
phenacemide
dosage and desirable plasma levels *4:* 262
phenobarbitone
dosage and desirable plasma levels *4:* 262
phenytoin
dosage and desirable plasma levels *4:* 262
primidone *4:* 264
status epilepticus
amylobarbitone sodium *4:* 265
diazepam *4:* 265
drug treatment *4:* 265–266
phenytoin *4:* 265
sulthiame
dosage and desirable plasma levels *4:* 262
Grand mal, centrencephalic
patho-physiology *4:* 233–234
Griseofulvin
blood levels *3:* 260
half-life *3:* 260
interaction with
barbiturates *3:* 121

H

Haematological reactions
antibacterial agents *4:* 140–141
Haematoma, perianal *4:* 78
Haemodialysis
cephalexin *3:* 62
dosage *3:* 73
Haemoglobin
cephalexin causing a fall *3:* 66

Haemolytic streptococcal infections
drugs of choice *3:* 6
β-Haemolytic streptococcal infections
benzylpenicillin
compared with
cephalexin *3:* 21–22
failures *3:* 22
recurrence *3:* 22
cephalexin
compared with
benzylpenicillin *3:* 21–22
failures *3:* 22
recurrence *3:* 22
β-Haemolytic streptococcal pharyngitis
cephalexin
compared with
cephaloglycin *3:* 22–23
cephaloglycin
compared with
cephalexin *3:* 22–23
see also pharyngitis, streptococcal
Haemophilus influenzae
cephalexin sensitivity *in vitro 3:* 47
Haemorrhage, gastro-intestinal
anticholinergics contra-indicated *3:* 382
Haemorrhoidectomy *4:* 78
Haemorrhoids
management of *4:* 75–80
Haemorrhoids, complicated
management of *4:* 78
Haemorrhoids, internal
anal dilatation *4:* 77–78
treatment *4:* 75–78
Half-life
actetohexamide *3:* 100, 102
antibacterial agents *3:* 261–263
chlorpropamide *3:* 100, 101
glibenclamide *3:* 100, 102
glymidine *3:* 100, 103
griseofulvin *3:* 260
lithium *4:* 352
metformin *3:* 103
phenformin *3:* 103
tolazamide *3:* 100, 102
tolbutamide *3:* 100, 101
Half-life, biological
amantadine *3:* 436
Half-life, plasma
acetazolamide *4:* 245, 251
anticonvulsant drugs *4:* 244–245
benzodiazepines *4:* 395
carbamazepine *4:* 245, 250
cephalexin *3:* 53, 56–57
neonates and infants *3:* 53, 56–57
renal failure *3:* 53, 56–57
cephaloridine *3:* 57
renal failure *3:* 57
cephalothin *3:* 57
renal failure *3:* 57
chlorpromazine *4:* 333
colaspase *3:* 234
cyclophosphamide *3:* 234
cytarabine *3:* 234
daunorubicin *3:* 234
diazepam *4:* 245, 250
digitoxin *3:* 258
digoxin *3:* 258
epicillin *3:* 317–318
ethosuximide *4:* 245, 249
meprobamate *4:* 395
6-mercaptopurine *3:* 234
methoin *4:* 244
methotrexate *3:* 234
methylphenobarbitone *4:* 244
minocycline *3:* 322
paracetamol *3:* 117
paramethadione *4:* 245
phenacemide *4:* 244
phensuximide *4:* 245
phenobarbitone *4:* 244, 248
phenytoin *4:* 244, 247
agents prolonging *4:* 276
prednisolone *3:* 234
primidone *4:* 244
sulthiame *4:* 245, 251
trimethadione *4:* 245, 249
Haloperidol
dosage guide *4:* 398
dosage relationships *4:* 339
structural formula *4:* 326, 329
Halothane
adverse reactions *3:* 113–114, 463–467; *4:* 104–107
influence on pancuronium dose *4:* 180
jaundice *3:* 113–114, 463–467
mortality *3:* 113–114
jaundice, post-halothane and previous administration *3:* 113–114
oxalic acid excretion *3:* 466–467
unintended exposure in surgical patients *4:* 104–107
Halothane + N_2O
operating conditions *4:* 173
Headache, cluster
pizotifen *3:* 164–169, 172–173, 180–181
Headache, epileptic
pizotifen *3:* 166–167
Headache, glyceryl trinitrate-induced
pizotifen effect *3:* 191–192
Headache, muscle contraction
pizotifen *3:* 166–167
Headache, post-traumatic
pizotifen *3:* 166–167
Headache, vascular
pizotifen *3:* 164–181
Headache, vasomotor
pizotifen *3:* 166–167
Heart attack
see infarction, myocardial
Heart block, complete
example of *4:* 286
Heart failure
see failure, heart
Heart rate
atropine effect on *3:* 432–433
neostigmine effect on *3:* 432–433
pancuronium effect on *4:* 202–205

Heart rhythm
atropine effect on *3:* 432–433
neostigmine effect on *3:* 432–433
Hemicranicus, status
pizotifen *3:* 168–169
Heparin
myocardial infarction
compared with
streptokinase *3:* 450–451
pulmonary embolism
compared with
streptokinase *3:* 280
septicaemia with disseminated intravascular coagulation *3:* 134
Hepatic disease
levodopa pharmacokinetics, influence on *4:* 59–60
Hepatic dysfunction
antibacterial agents host determinants *4:* 141
Hepatitis
halothane *3:* 463–467
Hepatitis, active chronic
corticosteroids *4:* 305–306
Hepatotoxicity
antibacterial agents *4:* 140–141
cytotoxic drugs *3:* 359
halothane *3:* 463–467
see also jaundice
Hexamine
in renal failure *3:* 264
Hexobarbitone
dosage: hypnotic *3:* 121
metabolism *3:* 121
Hexose monophosphate shunt
insulin *3:* 85
Histamine
migraine: role in *3:* 155
Histamine release
pancuronium effect on *4:* 191, 205
Hodgkin's disease
alkylating agents *3:* 341–343
chlorambucil *3:* 341
cyclophosphamide *3:* 341
drugs of choice *3:* 341–343
nitrogen mustard *3:* 341–342
treatment schedules *3:* 341–343
Homones, gut
insulin secretion: effect on *3:* 86
Host determinants
antibacterial agents *4:* 142–143
Hydrocarbons, fluorinated
blood levels in asthmatics after inhalations of pressurised aerosols *3:* 430
Hydrogen ion diffusion
peptic ulcer *3:* 369–370
12-Hydroxydigitoxin
see digoxin
5-Hydroxytryptamine
see serotonin
Hydroxyzine
dosage guide *4:* 398
structural formula *4:* 390
l-Hyoscyamine
duodenal ulcer *3:* 383
Hypercalcaemia
antacid therapy complication *3:* 377
Hyperchylomicronaemia
triglycerides, medium chain *3:* 124
Hyperparathyroid, primary
oestrogens
in postmenopause *4:* 108–110
Hypersensitivity reactions
cephalexin *3:* 66–68
Hypertension
adrenergic neurone blocking drugs *4:* 94, 98
α-adrenergic receptor blocking drugs *4:* 94, 98
β-adrenergic receptor blocking drugs *4:* 94, 98–99
amiloride *4:* 94–96
antihypertensive drug therapy *4:* 90–100
carbenoxolone sodium *3:* 386
clonidine *4:* 94, 97
contraceptives, oral
mode of action *3:* 111–112
spironolactone control *3:* 111
diuretics *4:* 94–96
drug treatment *4:* 93–99
ganglion blocking drugs *4:* 94, 97
α-methyldopa *4:* 94, 96–97
oestrogens, conjugated
spironolactone control *3:* 111
polypharmacy *4:* 93
renal disease: mechanism in *3:* 274–275
in renal failure
diazoxide *4:* 298–299
reserpine *4:* 94, 96–97
spironolactone *4:* 94–96
and strokes *3:* 452–453
thiazides *4:* 94–96
treatment approach *4:* 93
treatment results *4:* 99–100
Hypertension, pulmonary
drug-induced *4:* 301–302
Hypertension, renal
pathogenesis, hypothetical *3:* 275
Hypertriglyceridaemia, familial fat-induced
see hyperchylomicronaemia
Hypertrophy, prostatic
anticholinergics contra-indicated *3:* 384
Hypno-sedative drugs
absorption *3:* 120
adverse reactions *3:* 122
alcohols *3:* 119
anaesthesia *3:* 118–119
anticonvulsant properties *3:* 118–119
barbiturates *3:* 119
benzodiazepines *3:* 119
blood-brain barrier; passage across *3:* 118
carbamates *3:* 119
chemical classes *3:* 119
classification *3:* 118
compared with
tranquillisers *3:* 118–119
cyclic ethers *3:* 119
distribution *3:* 120
drug interactions *3:* 121
excretion *3:* 121–122
metabolism *3:* 120–121

muscle relaxant properties *3:* 118–119
placental transfer *3:* 120
pharmacodynamics *3:* 119
pharmacokinetics *3:* 118, 120–122
physical dependence *3:* 119
piperidinediones *3:* 119
protein binding *3:* 120
quinazolones *3:* 119
rational therapy with *3:* 122
respiratory depression *3:* 119
sedation *3:* 119
therapeutic goals *3:* 118
therapeutic misadventures *3:* 122
thiobarbiturates *3:* 119
toxicity *3:* 122
Hypnotics
insomnia; effect in *4:* 292–293
therapeutic goal *3:* 118
see also hypno-sedative drugs
Hypoglycaemic activity
biguanides *3:* 103
insulin preparations characteristics *3:* 95
insulin + sulphonylureas *3:* 91
sulphonylureas preparations *3:* 100–103
sulphonylureas + insulin *3:* 91
Hypoglycaemic agents, oral *3:* 88–94, 98–103
adverse reactions *3:* 220–222
arteriosclerosis, cerebral *3:* 219
biguanides *3:* 91–93, 99, 103
blood lipids: effect on *3:* 93–94
body weight: effect on *3:* 93–94
cardiovascular disease *3:* 215–216, 219, 222–224
cardiovascular mortality *3:* 222–224
clinical pharmacological aspects *3:* 79–107
clinical and therapeutic aspects *3:* 204–226
coronary artery disease *3:* 219
in diabetes insipidus *3:* 94
drug interactions *3:* 224–225
liver disease *3:* 220
mode of action
biguanides *3:* 91–93
aerobic glycolysis inhibition *3:* 92
glucose, absorption impairment *3:* 93
glucose, peripheral utilisation increased *3:* 92
specific enzyme inhibition *3:* 93
sulphonylureas *3:* 88–91
pancreas β-cell stimulation *3:* 89–90
hepatic glucose release inhibition *3:* 90
peripheral effects *3:* 91
physiological aspects *3:* 79–107
renal disease *3:* 220
sulphonylureas *3:* 88–91, 99–103
therapeutic use *3:* 214–217
thyroid function: effect on *3:* 94
Hypokalaemia
carbenoxolone sodium *3:* 386–387
Hypokalaemia, drug-induced
digitalis sensitivity *3:* 259
Hypotension
levodopa *4:* 63
Hypothermia
pancuronium: precautions *4:* 220
Hypothyroidism
lithium treatment causing? *3:* 457
Hypsarrhythmia
EEG pattern, typical *4:* 232

I

Ichthyosis
ointments for *4:* 430–431
treatment *4:* 430–431
Imipramine
adverse reactions *4:* 384–385
dosage and plasma levels correlation *4:* 371
dosage guide *4:* 378
metabolism *4:* 370–372
structural formula *4:* 366
toxic doses *4:* 384
Immune response
mechanisms operating *3:* 231–232
Immunisation
measles *4:* 110–111
rubella *4:* 111–112
Immunosuppression
lymphomas, intracerebral *4:* 113–114
skin cancer *4:* 123
Immunosuppressive drugs
adverse reactions *3:* 352–365
biochemical and clinical pharmacological considerations *3:* 227–253
therapeutic problems *3:* 352–365
therapeutic uses *3:* 331–332
Immunosuppressive therapy *3:* 347–348
choice of drug *3:* 333–335
dosage schedule *3:* 333–335
malignant tumours *3:* 362–363
rheumatic disorders *3:* 129–131
Indolic derivatives
molindone *qv*
Indomethacin
osteoarthritis *3:* 132
Infantile spasms
see seizures, minor motor
Infants
cephalexin
absorption *3:* 55–56
dosage *3:* 71
half-life, serum *3:* 53, 56
milk feeding influence *3:* 56
Infarction, cerebral
causing cerebral oedema
glycerol treatment *4:* 431–432
Infarction, myocardial
acute phase of *3:* 448–449
arrhythmia characteristics *4:* 285–286
atropine *3:* 448
cardiac slowing major problem in prehospital phase *3:* 448
clofibrate *4:* 101–105
diagnosis *4:* 284–285
morphine *4:* 285
natural history of *3:* 447
pain and anxiety relief *4:* 285
streptokinase *3:* 451–452
thrombolytic therapy *3:* 450–451

transfer of patient to coronary care unit *4:* 288–289
ventricular fibrillation: antiarrhythmic agents failure to control *3:* 281–282
Infarction, myocardial, acute
heparin
compared with streptokinase *3:* 450–451
home and hospital treatment *3:* 449–450
management in general practice *4:* 283–289
streptokinase
compared with
heparin *3:* 450–451
Infection
cytotoxic drugs *3:* 356–357
Infections, miscellaneous
cephalexin *3:* 41–42
paediatrics *3:* 36
Inoculum size
cephalexin activity influenced by *3:* 44–48
Inotropic effect
digoxin *3:* 405
Insomnia
associated factors *4:* 291–292
drugs *4:* 292
factors extrinsic to the patient *4:* 292
factors intrinsic to the patient *4:* 291
classification *4:* 291–292
drug causing *4:* 292
hypnotic drug effects *4:* 292–293
management of *4:* 290–294
treating the practical problem *4:* 293–294
Insulin
adverse reactions *3:* 220
biosynthesis *3:* 87
chemical properties *3:* 86–87
clinical pharmacological aspects *3:* 79–107
clinical and therapeutic aspects *3:* 204–226
degradation *3:* 87
glucathione dependence *3:* 87
diabetes mellitus: insufficency of *3:* 88
electrophoretic determination *3:* 87
food storage induction *3:* 85
methods of *3:* 85
glycogen synthesis *3:* 85
hexose monophosphate shunt *3:* 85
hypoglycaemic effect
sulphonylureas synergy *3:* 91
insufficiency in diabetes mellitus *3:* 88
metabolic effects *3:* 85
physical properties *3:* 86–87
physiological aspects *3:* 79–107
precursor *3:* 87, 88
secretion *3:* 85
absence of *3:* 85
glucose influence on *3:* 86
gut hormones influence on *3:* 86
non-carbohydrate metabolites influence on *3:* 86
regulation *3:* 86
vagotomy influence on *3:* 86
structure *3:* 86–87
synthesis *3:* 87
therapeutic use *3:* 213–214
transport *3:* 87
carriage in plasma *3:* 87
Insulin, biphasic *3:* 95, 98
duration of action *3:* 95
Insulin, endogenous plasma
components *3:* 87
Insulin, globin *3:* 95, 97
duration of action *3:* 95
Insulin, isophane *3:* 95, 96–97
duration of action *3:* 95
Insulin, neutral *3:* 95, 97–98
duration of action *3:* 95
Insulin preparations *3:* 94–98
diabetes mellitus *3:* 94–98
hypoglycaemic activity characteristics *3:* 95
insulin, biphasic *3:* 95, 98
insulin, globin *3:* 95, 97
insulin, isophane *3:* 95, 96–97
insulin, neutral *3:* 95, 97–98
insulin, protamine zinc *3:* 95, 96
insulin, regular *3:* 95–96
insulin, zinc suspension (lente) *3:* 95, 97
special insulins *3:* 98
synthetic *3:* 95
Insulin, protamine zinc *3:* 95, 96
combined with
insulin, regular *3:* 96
duration of action *3:* 95
Insulin, regular *3:* 95–96
combined with
insulin, protamine zinc *3:* 96
Insulin, regular (crystalline)
duration of action *3:* 95
Insulin, zinc suspension (lente) *3:* 95, 97
duration of action *3:* 95
Insulin, zinc suspension amorphous (semi-lente) *3:* 95, 97
duration of action *3:* 95
Insulin, zinc suspension crystalline (ultra-lente) *3:* 95, 97
duration of action *3:* 95
Intestine, small
lactulose: direct action *4:* 41
Intraocular penetration
cephalexin *3:* 58
glaucoma *3:* 467–468
Intubation
pancuronium *4:* 174–175
compared with
suxamethonium *4:* 184
d-tubocurarine *4:* 184–186
Irradiation, gastric
peptic ulcer *3:* 391
Irritable colon syndrome
anticholinergic drugs *3:* 396
diagnosis *3:* 396
treatment *3:* 396
Ischaemia
clofibrate *4:* 101–105
Isocarboxazid
dosage guide *4:* 378
structural formula *4:* 366
Isoniazid
interaction with
phenytoin *4:* 276, 279
Isoprenaline
heart failure *4:* 288

nebulised with mucolytic agents
clinical and physiological evaluation *3:* 127–128
Isoproterenol
see isoprenaline

J

Jaundice
halothane *3:* 113–114
mortality *3:* 113–114
see also hepatotoxicity
Jaundice, post halothane
halothane, previous administration *3:* 113–114

K

Kanamycin
in renal failure *3:* 264
Keflex
see cephalexin
Keforal
see cephalexin
Keratoses, solar
fluorouracil *3:* 286
Kidney
see renal
Klebsiella-Enterobacter spp.
cephalexin sensitivity *in vitro 3:* 45–47
Klebsiella pneumoniae
cephalexin sensitivity *in vitro 3:* 47
Krebs cycle
see citric acid cycle

L

Laboratory test modifications
cephalexin *3:* 69–70
Lactulose
absorption *4:* 42–43
acidorrhoea, faecal *4:* 34–37, 40–41
adverse reactions *4:* 12, 17, 24, 29–31, 45
ammonia intoxication, congenital disorders *4:* 28
ammonia metabolism, cerebral *4:* 37
ammonia transport, colonic *4:* 34–37
blood ammonia levels *4:* 39
constipation *4:* 29–31, 39–41
diarrhoea *4:* 45
dosage *4:* 12–13, 14–16, 18, 22, 24, 27, 28, 29–31, 45–46
adult *4:* 46
children *4:* 46
constipation *4:* 46
encephalopathy, portal systemic *4:* 45–46
dysmorphology *4:* 42
encephalopathy, portal systemic *4:* 11–28
compared with
chlortetracycline *4:* 21–23
neomycin *4:* 14–24
sorbitol *4:* 18–19
excretion *4:* 43–44
indications for use *4:* 44
interactions *4:* 4–6
metabolism *4:* 43
mode of action *4:* 32–33
constipation *4:* 39–41
encephalopathy, portal systemic *4:* 33–39
+ neomycin *4:* 4–6
blood ammonia levels *4:* 39
pharmacodynamic studies *4:* 32–42
pharmacokinetics *4:* 42–44
precautions in use *4:* 45
reproduction studies *4:* 42
small intestine
direct action on *4:* 41
therapeutic trials *4:* 11–31
therapeutic use, a rationale approach *4:* 7–48
toxicology studies *4:* 41–42
Laevolac
see lactulose
Lanoxin
see digoxin
Lanoxin PG
see digoxin
Laroxyl
see amitriptyline
Leeds technique
psoriasis *4:* 87
Lethargy
phenytoin intoxication *4:* 260
Leucopenia
associated with co-trimoxazole after renal transplantation *4:* 128–129
Leukaemia, acute
colaspase *3:* 335
cyclophosphamide *3:* 335
drugs of choice *3:* 335
treatment schedules *3:* 335–336
Leukaemia, granulocytic, chronic
busulphan *3:* 338–339, 354–355
treatment schedules *3:* 338–339
Leukaemia, lymphoblastic, acute
drugs of choice *3:* 336–337
methotrexate *3:* 336–337
treatment schedules *3:* 336–337
vincristine *3:* 336–337
Leukaemia, lymphocytic, chronic
chlorambucil *3:* 339
prednisone *3:* 339–340
treatment schedules *3:* 339–340
Leukaemia, myeloblastic, acute
drugs of choice *3:* 337–338
treatment schedules *3:* 337–338
Leukaemia of childhood, lymphoblastic, acute
see leukaemia, lymphoblastic, acute
Leurocristine
see vincristine
Levodopa
absorption *4:* 56–57
adverse reactions *4:* 63–65
cardiovascular effects *4:* 60, 64
contra-indications *4:* 65–66
decarboxylase inhibition of metabolism *4:* 60–61
decarboxylation *4:* 57–59
distribution *4:* 57
dyskinesia *4:* 63–64
endocrine effects *4:* 60
excretion *4:* 57–60
failures *4:* 66–67
gastro-intestinal effects *4:* 63–64

hypotension *4:* 63
increased mobility, effects consequent on *4:* 65
interactions *4:* 66
metabolism *4:* 57–60
3-O-methylation *4:* 58–59
micturition: effect on *4:* 64–65
miscellaneous reactions *4:* 65
nausea and vomiting *4:* 63–64
ocular effects *4:* 64
pharmacology *4:* 56–61
pharmacokinetics *4:* 56–60
hepatic disease influence *4:* 59–60
renal disease influence *4:* 59–60
psychiatric reactions *4:* 63, 65
structural formula *4:* 55
treatment, general principles *4:* 62–63
Lidocaine
see lignocaine
Ligation, rubber ring
pile or rectal mucosa prolapse *4:* 77
Lignocaine
adverse reactions *4:* 287
ventricular arrhythmias *4:* 286–287
Lincomycin
in renal failure *3:* 264
Lip cancer
cause and prevention *3:* 469–470
Lipids, blood
biguanides effect on *3:* 93–94
hypoglycaemic agents, oral effect on *3:* 93–94
Liquorice, deglycyrrhizinated
gastric ulcer *3:* 389–390
Lithium
adreno-cortical activity *3:* 456–457
adverse reactions *4:* 355–357
cerebrospinal fluid concentration *4:* 352
complications *4:* 355–357
depressions, acute *4:* 351
dosage
mania *4:* 354–355
pharmacological determinants *3:* 285
dysmorphogenicity *4:* 357
excretion *4:* 353
half-life, two phases *4:* 352
hypothyroidism during treatment *3:* 457
indications for use *4:* 349–351
mania *4:* 353–355
concomitant treatment *4:* 353–354
manic-depressive illness *3:* 456–458
mode of action *3:* 457–458
mode of action *3:* 457–458; *4:* 351–352
pharmacokinetics *4:* 352–353
poisoning *4:* 353
pregnancy: use during *4:* 357
prophylaxis in recurrent affective disorders *3:* 284–285
psychosis, manic-depressive
maintenance therapy *4:* 350
manic phase *4:* 349
schizo-affective disorder, excited *4:* 350–351
schizophrenia and other disorders *4:* 351
serum concentration, monitoring *4:* 355
special psychotherapeutic properties *4:* 349
thyroid enlargement *4:* 355–356
toxicity *4:* 353, 356
Lithium carbonate
see lithium
Liver
gluconeogenesis *3:* 83–84
Liver damage
methotrexate in psoriasis *3:* 267–268
see also hepatotoxicity
necrosis, hepatic
Liver disease
hypoglycaemic agents, oral *3:* 220
pancuronium duration of action: effect of *4:* 172
pancuronium: precautions *4:* 219
Lower respiratory tract infections
cephalexin *3:* 15–19
bacteriological results *3:* 16
therapeutic results *3:* 16
paediatrics
cephalexin *3:* 34
Luminal
see phenobarbitone
Lung abscess
cephalexin *3:* 16
Lung abnormalities
nitrofurantoin *3:* 112–113
Lung function tests
chronic bronchitis *4:* 84
Lymphadentis
cephalexin *3:* 36
Lymphangiectasia, intestinal
triglycerides, medium chain *3:* 124
Lymphoma, follicular
treatment schedules *3:* 340
Lymphomas, intracerebral
immunosuppression *4:* 122–123
Lymphosarcoma
chlorambucil *3:* 340
treatment schedules *3:* 340–341
Lymphosarcoma, stage I
prognosis *3:* 135–136
radiotherapy *3:* 136

M

Macrolides
in renal failure *3:* 265
Malabsorption syndrome
digoxin absorption in patients with *4:* 426–427
Mania
antimanic drugs *4:* 347–357
as a symptom *4:* 347
lithium *4:* 353–355
concomitant treatment *4:* 353–354
lithium dosage *4:* 354–355
pathogenetic mechanisms *4:* 347–348
treatment: various approaches *4:* 348
unipolar and bipolar affective disorders *4:* 347
Manic-depressive illness
lithium *3:* 456–458
lithium: mode of action *3:* 457–458
Manic-depressive psychosis
see psychosis, manic-depressive

MAO inhibitors
adverse reactions *4:* 386
chemical types *4:* 365–366
hydrazide
dosage guide *4:* 378
interactions *4:* 384
non-hydrazide
dosage guide *4:* 378
monoamine oxidase inhibitors
structural formulae *4:* 366
toxic doses *4:* 386
Marihuana
bronchitis *4:* 428–429
cerebral atrophy in young smokers of *3:* 268–269
in man *3:* 269–270
medical manifestations associated with *4:* 428–429
Maxolon
see metoclopramide
MBC
see minimum bactericidal concentration
3MC
phenytoin metabolism: influence on *4:* 272
MCT
see triglycerides, medium chain
Measles
vaccination *4:* 110–111
Media
cephalexin activity influenced by *3:* 44–48
Medicines
control comparison of UK and USA *3:* 309–312
control in UK *3:* 305–308
control in USA *3:* 308–309
doctors and their use of *3:* 312–313
Medroxyprogesterone
acromegaly *4:* 303
Melphalan
dosage
myelomatosis *3:* 135
mode of action *3:* 235
myelomatosis *3:* 344–345
compared with
cyclophosphamide *3:* 135
pharmacokinetics *3:* 234
Meniere's syndrome
treatment *4:* 118–121
Meningitis, purulent neonatal
treatment *3:* 133
Meningococcal carriers
cephalexin *3:* 42
failure *3:* 42
minocycline *3:* 324
Mental deficiency
psychotherapeutic drugs *4:* 403
limitations of drug therapy *4:* 403
Mephenytoin
see methoin
Meprobamate
dosage guide *4:* 398
half-life, plasma *4:* 395
pharmacological properties *4:* 394
structural formula *4:* 390
2-Mercaptoethane sulphate
compared with N-acetyl-cysteine *3:* 127–128
6-Mercaptopurine
half-life, plasma *3:* 234
pharmacokinetics *3:* 234
protein binding *3:* 234
Mesantoin
see methoin
Mesontoin
see methoin
Mesoridazine
dosage relationships *4:* 339
structural formula *4:* 328
Metabolites, non-carbohydrate
insulin secretion: effect on *3:* 86
Metformin
absorption *3:* 103
excretion *3:* 103
half-life *3:* 103
hypoglycaemic activity characteristics *3:* 103
pharmacokinetics *3:* 103
structural formula *3:* 99
Methacycline
antibacterial activity *3:* 321
excretion rate *3:* 323
Methamphetamine
dosage guide *4:* 378
structural formula *4:* 366
Methdilazine
adverse reactions *3:* 176
dosage in migraine *3:* 176
Methenamine
see hexamine
Methicillin
cross resistance
cephalexin *3:* 51
in renal failure *3:* 264
Methicillin-resistance
see penicillin resistant infections
Methohexitone
dosage: hypnotic *3:* 121
metabolism *3:* 121
Methoin
grand mal
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 244
pharmacokinetic properties *4:* 244
Methotrexate
acute lymphoblastic leukaemia *3:* 336–337
adverse reactions *4:* 88
carcinoma of the head and neck *3:* 346
chloriocarcinoma *3:* 346
half-life, plasma *3:* 234
liver damage in psoriasis *3:* 267–268
mode of action *3:* 235
pharmacokinetics *3:* 234
protein binding *3:* 234
psoriasis *4:* 87–88
reticulum cell sarcoma *3:* 341
Methotrimeprazine
analgesia, postoperative
compared with pethidine *4:* 310–311
Methoxyflurane
influence on pancuronium dose *4:* 180
oxalic acid excretion *3:* 466–467

Methoxyflurane + N_2O
operating conditions *4:* 173
Methsuximide
seizures, mixed
dosage and desirable plasma levels *4:* 262
α-Methyldopa
hypertension *4:* 94, 96–97
3-*O*-Methyldopa
Parkinsonism *4:* 71
Methylergol carbamide maleate
dosage in migraine *3:* 176
Methylphenidate
dosage guide *4:* 378
interaction with
phenytoin *4:* 276
structural formula *4:* 366
Methylphenobarbitone
half-life, plasma *4:* 244
pharmacokinetic properties *4:* 244
Methysergide
adverse reactions *3:* 176
dosage in migraine *3:* 176, 177–178
migraine
compared with pizotifen *3:* 173–174, 178
serotonin antagonist *3:* 154
Metoclopramide
peptic ulcer *3:* 397
pharmacological emptying of stomach *3:* 295–296
Metronidazole
trichomoniasis *4:* 424–425
vaginitis *3:* 461–462
Metyrapone
interaction with phenytoin *4:* 278
MIC
see minimum inhibitory concentration
Micturition
levodopa effect on *4:* 64–65
Midone
see primidone
Migraine
acute attack
ergotamine tartrate *3:* 156
antiserotonin agents effect *3:* 185
biogenic amines, role in *3:* 183
bradykinin, role in *3:* 155
classic or common
pizotifen *3:* 163–180
dimethothiazine *3:* 201
drug control *3:* 156–158, 163–180
histamine, role in *3:* 155
methysergide
compared with
pizotifen *3:* 177–178
noradrenaline role in *3:* 154–155
pathogenesis and interval treatment *3:* 153–158
pizotifen *3:* 156–157
compared with
dimethothiazine *3:* 201
methysergide *3:* 177–178
other prophylatic agents *3:* 175–178
placebo *3:* 172–175
serotonin antagonists *3:* 176–178
long-term studies *3:* 179–180
prophylactic agents
cyproheptadine *qv*
methdilazine *qv*
methylergol carbamide maleate *qv*
methysergide *qv*
pizotifen *qv*
serotonin antagonists *qv*
prostaglandins, role in *3:* 156
serotonin relationship *3:* 184–185
serotonin, role in *3:* 154, 182–183
tyramine, role in *3:* 155
vasoactive substances, effect *3:* 185–186
Milk alkali syndrome
antacid therapy complication *3:* 377
Milk feeding
cephalexin: influence on *3:* 56
Milontin
see phensuximide
Minimum bacterial concentrations
cephalexin *3:* 44–46
Minimum inhibitory concentrations
cephalexin *3:* 44–46
Minocin
see minocycline
Minocycline
absorption *3:* 322
adverse reactions *3:* 325
antibacterial activity *3:* 319–322
distribution *3:* 322
dosage *3:* 323–326
drug interactions *3:* 325
excretion *3:* 322–323
gonorrhoea *3:* 324
meningococcal carriers *3:* 324
pharmacokinetics *3:* 322–323
precautions in use *3:* 325
pregnancy *3:* 325
resistance to *3:* 322
serum half-life *3:* 322
serum levels *3:* 322
structural formula *3:* 320
therapeutic trials *3:* 323–324
Minomycin
see minocycline
Miscarriage rates
anaesthetists and theatre nurses *3:* 433–434
Mogadon
see nitrazepam
Molindone
structural formula *4:* 326
Monamine oxidase inhibitors
see MAO inhibitors
Monoamines
neurotransmission *4:* 54
Morphine
myocardial infarction *4:* 285
Mucolytic agents
N-acetyl-cysteine *qv*
2-mercaptoethane sulphate *qv*
nebulised with isoprenaline
clinical and physiological evaluation *3:* 127–128
Mucous membrances
cytotoxic drugs effect on *3:* 358

Muscle relaxants
hypno-sedatives drugs *3:* 118–119
see also neuromuscular blocking agents
Muscle relaxants, centrally acting
interaction with
non-depolarising skeletal muscle relaxants *4:* 215–216
Muscle relaxants, skeletal
non-depolarising
interaction with
antiarrhythmic agents *4:* 214, 217
antibiotics *4:* 213–214, 216
anticholinesterases *4:* 214
diuretics *4:* 215, 217
ganglion blocking agents *4:* 215
muscle relaxants, centrally acting *4:* 215–216
Mutagenicity
cytotoxic drugs *3:* 360
Mycoplasma pneumoniae infections
drugs of choice *3:* 7
Mydriatric drugs
fundal inspection *3:* 468
Myelofibrosis
alkylating agents *3:* 344
Myelomatosis
cyclophosphamide
compared with
melphalan *3:* 135
drugs of choice *3:* 344–345
melphalan *3:* 344–345
compared with cyclophosphamide *3:* 135
treatment schedules *3:* 344–345
Myeloradiculoneuritis
rubella vaccine *4:* 112–113
Myocardial infarction
see infarction, myocardial
Myocardial response
digoxin *3:* 405
Myopathy
chloroquine *4:* 126
Myositis
carbenoxolone sodium *3:* 387
Mysoline
see primidone

N

Na-97
see pancuronium
NADP
nicotinamide-adenine-dinucleotide phosphate
role in glycolytic pathway *3:* 82
Nalidixic acid
in renal failure *3:* 264
urinary tract infection
primary treatment *3:* 416
Narcotics
adolescent girls: factors associated with progression to *3:* 271
overdosage *4:* 407
Necrosis, avascular
corticosteroid-induced *4:* 126–127
Necrosis, hepatic
paracetamol *3:* 117–118
Neisseria gonorrhoeae
cephalexin sensitivity *in vitro 3:* 47
Neomycin
blood ammonia levels *4:* 39
encephalopathy, portal systemic
compared with
lactulose *4:* 14–24
enteropathogenic *Esch. coli* diarrhoeal disease *4:* 306–307
+ lactulose *4:* 4–6
blood ammonia levels *4:* 39
in renal failure *3:* 264
Neonates
cephalexin
half-life, serum *3:* 53, 56–57
meningitis, purulent
treatment *3:* 133
Neostigmine
heart rate: effect on *3:* 432–433
heart rhythm: effect on *3:* 432–433
Nephropathy, analgesic
a review *4:* 124–125
Nephrosis, childhood
cyclophosphamide
compared with
prednisone *3:* 468–469
Nephrotoxicity
antibacterial agents *4:* 140–141
cephaloridine *3:* 4
Neuralgia, facial
pizotifen *3:* 166–167
Neuralgia, migrainous
see headache, cluster
Neuroleptanalgesia
influence on pancuronium dose *4:* 180
Neuroleptanalgesia + N_2O
operating conditions *4:* 173
Neurological effects
antipsychotic drugs *4:* 345–346
antibacterial agents *4:* 140–141
host determinant *4:* 142
Neuromuscular blocking activity
pancuronium *4:* 190, 195–198
Neuromuscular blocking agents
pancuronium *qv*
protein binding *4:* 156
rational use of *4:* 153–162
suxamethonium *qv*
Neuron, epileptic
patho-physiology *4:* 235–236
Neurotoxicity
vincristine *3:* 358
Neurotransmitter substances
acetylcholine *4:* 53
in the central nervous system *4:* 53–56
monoamines *4:* 54
Neutral protamine Hagedorn insulin
see insulin, isophane
Neutropenia, reversible
cephalexin *3:* 65
Nialamide
dosage guide *4:* 378
structural formula *4:* 366

Nicotinic acid
intraocular pressure in glaucoma *3:* 467–468
Nitrazepam
seizures, minor motor *4:* 265
dosage and desirable plasma levels *4:* 262
Nitrofurantoin
adverse reactions *3:* 112–113
hypersensitivity *3:* 112–113
lung abnormalities *3:* 112–113
pulmonary fibrosis *3:* 113
in renal failure *3:* 264
urinary tract infections
compared with
cephalexin *3:* 31–32
primary treatment *3:* 416
Nitrogen mustard
Hodgkin's disease *3:* 341–342
mode of action *3:* 235
reticulum cell sarcoma *3:* 341
Nitrous oxide
pain relief in hospitals *3:* 273–274
Noradrenaline
migraine; role in *3:* 154–155
structural formula *4:* 55
see also monoamines
Noradrenaline hypothesis
depression *4:* 369–370
Noradrenergic synapse, central
mode of *4:* 368
Norepinephrine
see noradrenaline
Nortriptyline
dosage guide *4:* 378
plasma levels *3:* 427
structural formula *4:* 366
therapeutic effect *3:* 427
Novobiocin
in renal failure *3:* 265
NPH
neutral protamine Hagedorn
see insulin, isophane
NPH insulin
see insulin, isophane
Nucleic acids
synthesis *3:* 230–231
Nurses, theatre
high miscarriage rates *3:* 433–434
Nystagmus
phenytoin intoxication *4:* 260
Nystatin
candidiasis *4:* 424

O

Obesity
chlorphentermine *4:* 415
diethylpropion *4:* 414
drug treatment, ancillary *4:* 413–416
fenfluramine *4:* 415–416
management of *4:* 411–418
glucose tolerance test *3:* 209
phentermine *4:* 415
surgical treatment *4:* 416
treatment: suggested approach to *4:* 416–417
Ocular effects
levodopa *4:* 64
Oedema, cerebral
due to acute cerebral infarction
glycerol treatment *4:* 431–432
Oesophagitis reflux
antacid therapy *3:* 395
anticholinergics contra-indicated *3:* 382
carbenoxolone sodium *3:* 395
diagnosis *3:* 395
Oestrogens
peptic ulcer *3:* 390–391
primary hyperparathyroid
in postmenopause *4:* 108–110
vaginitis, atrophic *4:* 425
Oestrogens, conjugated
hypertension
spironolactone control *3:* 111
Olive oil
ear wax solvent efficacy *3:* 125
Operating conditions
ethrane + N_2O *4:* 173
forane + N_2O *4:* 173
halothane + N_2O *4:* 173
methoxyflurane + N_2O *4:* 173
neuroleptanalgesia + N_2O *4:* 173
pancuronium *4:* 172–174
Opiate addict
maintenance therapy during rehabilitation *4:* 407
Opiates
abuse of *4:* 406–407
extent of problem *4:* 406
withdrawal reactions *4:* 406–407
Oracef
see cephalexin
Oral contraceptives
see contraceptives, oral
Ospolot
see sulthiame
Osteoarthritis
aspirin *3:* 132
drug therapy *3:* 289–290
phenylbutazone *3:* 132
physiotherapy *3:* 290
indomethacin *3:* 132
silicone: lubricant in joints *3:* 288–289
surgical therapy *3:* 290
Osteoarthritis, knee
non-steroid anti-inflammatory drugs *3:* 132
Osteomyelitis
antibacterial agents *4:* 130–139
cephalexin *3:* 40–41
compared with
other cephalosporins *3:* 40
penicillin derivatives *3:* 40
failure *3:* 41
cephalexin, long-term *3:* 41
cephalosporin
compared with cephalexin *3:* 40
penicillin-resistant
cephalexin *3:* 40–41
Osteoporosis
and postmenopause *4:* 108–110

Otitis media
cephalexin *3:* 21
management in general practice *3:* 418–421
Otitis media, acute
antibacterial agents *4:* 138–139
cephalexin *3:* 20
Otitis media, acute suppurative
antibacterial agents *3:* 419
treatment *3:* 418–419
Otitis media, bacterial
infants and young children
drug of choice *3:* 6
Otitis media, chronic
cephalexin *3:* 20
treatment *3:* 420–421
Otitis media, secretory
treatment *3:* 420
Ototoxicity
antibacterial agents *4:* 140–141
Oxalic acid
excretion
after halothane *3:* 466–467
after methoxyflurane *3:* 466–467
Oxazepam
dosage guide *4:* 398
structural formula *4:* 390
Oxazolidine-2,4-diones
paramethadione *qv*
trimethadione *qv*
Oxidative pathway, direct
see hexose monophosphate shunt
Oxypertine
structural formula *4:* 326
Oxytetracycline
antibacterial activity *3:* 321
protein metabolism *4:* 429–430

P

^{32}P phosphorus, radioactive
polycythemia vera *3:* 343
Paediatrics
cephalexin *3:* 34, 36
lower respiratory tract infections
cephalexin *3:* 34
miscellaneous infections
cephalexin *3:* 36
triglycerides, medium chain *3:* 124–125
upper respiratory tract infections
cephalexin *3:* 36
urinary tract infections
cephalexin *3:* 36
Paget's disease of bone
diphosphonates *3:* 444–445
human calcitonin *3:* 444
treatment *3:* 444–445
nitrous oxide use in hospitals *3:* 273–274
Pancreas, β-cells
sulphonylurea stimulation *3:* 89–90
Pancreatic damage
colaspase *3:* 359
Pancreatic insufficiency
vitamin B_{12} malabsorption *3:* 287

Pancuronium
absorption *4:* 208
acetylcholine release: effect of *4:* 191
adverse reactions *4:* 189, 211–212
compared with
d-tubocurarine *4:* 189
anaesthesia: effects on *4:* 200
anticholinergic activity *4:* 207–208
atropine-like activity *4:* 190
blockade reversal *4:* 179–182, 188–189, 199–200, 221
compared with
d-tubocurarine *4:* 188–189
blood pressure effect *4:* 201–203
type of surgery *4:* 177
cardiovascular effects *4:* 176–179, 186–187, 192–193, 201–205, 222
compared with
alcuronium *4:* 186
gallamine *4:* 186
d-tubocurarine *4:* 186–187
catecholamine blood levels *4:* 207
clinical use *4:* 159–161
cumulative effect *4:* 198
dehydration
precautions *4:* 220
distribution *4:* 208–209
dosage *4:* 159–160, 171–172, 220–221
dose requirement
primary anaesthetic influence *4:* 180
dose-response curve *4:* 197
duration of action *4:* 170–172, 187–188
compared with
alcuronium *4:* 187
d-tubocurarine *4:* 187–188
liver disease effect on *4:* 172
dysmorphology studies *4:* 195
ease of intubation *4:* 174–175
effect of prior suxamethonium administration *4:* 198
effect of supplementary doses *4:* 175–176
electrolyte disturbance
precautions *4:* 220
evaluation critique *4:* 157–159
excretion *4:* 210
ganglion blocking activity *4:* 190
haemodynamic effects *4:* 201–205, 222
heart rate effect *4:* 202–205
histamine release activity *4:* 191–205
hormonal effects *4:* 193
hypothermia
precautions *4:* 220
indications for use *4:* 211
interaction with
anaesthetics *4:* 191–192, 200–201
intubation *4:* 184–186
compared with
suxamethonium *4:* 184
d-tubocurarine *4:* 184–186
liver disease
precautions *4:* 219
metabolism *4:* 209–210
neuromuscular blocking activity *4:* 190, 195–198

onset of action *4:* 170–172, 183–184
compared with
alcuronium *4:* 183
gallamine *4:* 183
d-tubocurarine *4:* 183–184
operating conditions *4:* 172–174
pH alteration
precautions *4:* 220
pharmacodynamic studies *4:* 189–208
pharmacokinetic studies *4:* 208–210
placental transfer *4:* 209
potency in conscious subjects
compared with
alcuronium *4:* 196
d-tubocurarine *4:* 196
precautions in use *4:* 218–220
general *4:* 218
in presence of associated disease *4:* 219–220
rational use of *4:* 153–162
renal disease
precautions *4:* 219–220
respiration: effect of *4:* 205
a review *4:* 163–226
serum protein level effect *4:* 206
skeletal muscles: effect of *4:* 190–191
structural formula *4:* 211
therapeutic trials *4:* 170–189, 221–222
comparative *4:* 182–189
uncontrolled *4:* 170–182
toxicology studies *4:* 193–195
ventilation level effect *4:* 206–207
Paracetamol
half-life, plasma *3:* 117
hepatic necrosis *3:* 117–118
metabolism *3:* 117
overdosage *3:* 117–118
toxicity *3:* 117–118
Paracolon bacilli
cephalexin sensitivity *in vitro 3:* 45
Paradione
see paramethadione
Paraldehyde
excretion *3:* 121–122
Paramethadione
dysmorphology *3:* 108–109
epileptic pregnant patients
dysmorphology *3:* 109
half-life, plasma *4:* 245
petit mal
dosage and desirable plasma levels *4:* 262
pharmacokinetic properties *4:* 245
pregnancy *3:* 108–109
Parkinsonism
β-adrenergic receptor blocking drugs *4:* 70
aetiology *4:* 52
amantadine *4:* 68–69
amphetamine *4:* 69–70
anticholinergic drugs *4:* 67–68
antihistamines *4:* 69
apomorphine *4:* 69
catechol-*O*-methyl transferase inhibitors *4:* 70
decarboxylase inhibitors, peripheral *4:* 70
3-*O*-methyldopa *4:* 71
physiotherapy *4:* 71
psychotrophic drugs *4:* 70
stereotactic surgery *4:* 71
treatment, non-drug *4:* 71
Pavulon
see pancuronium bromide
Penfluridol
structural formula *4:* 328
Penicillin
adverse reactions *3:* 286–287
antibacterial activity *3:* 2
cephalexin cross-allergenicity *3:* 67–68
cephalexin cross-immunogenicity *3:* 67–68
cephalosporins cross-allergenicity *3:* 67–68
cephalosporins cross-immunogenicity *3:* 67–68
cross-allergenicity with cephalexin *3:* 67–68
cross-allergenicity with cephalosporins *3:* 67–68
cross-resistance with cephalexin *3:* 51–52
derivatives *3:* 2
epicillin *qv*
in renal failure *3:* 264–265
skin tests for sensitivity *3:* 286–287
Penicillin derivatives
osteomyelitis
compared with
cephalexin *3:* 40
Penicillin resistant infections
cephalexin *3:* 51
osteomyelitis
cephalexin *3:* 40–41
Pentobarbitone
dosage: hypnotic *3:* 121
metabolism *3:* 121
Pentylenetetrazol stimulation
anticonvulsant drug effect *4:* 239
Peptic ulcer
antacid therapy *3:* 374–380
bowel function disturbance *3:* 377
complications *3:* 377–379
current status *3:* 379–380
hypercalcaemia *3:* 377
intestinal obstruction *3:* 379
milk alkali syndrome *3:* 377
pharmacological basis *3:* 375–376
phosphorous depletion syndrome *3:* 379
renal calculi *3:* 377–378
sodium toxicity *3:* 378
anticholinergic drug indication *3:* 382
anticholinergics drugs *3:* 380–384
antipepsin agents *3:* 390
anti-ulcer therapy *3:* 373
carbenoxolone sodium *3:* 384–390
diagnosis *3:* 371–372
diet *3:* 392
emotional factors *3:* 391–392
exfoliative cytology *3:* 372
future treatment? *3:* 395
gastric biopsy *3:* 371–372
gastric irradiation *3:* 391
gastric secretion *3:* 372
hospital admission *3:* 374
medical management *3:* 366–403
metoclopramide *3:* 397

oestrogens *3:* 390–391
sedation *3:* 392
smoking cessation *3:* 374
SN 263 *3:* 390
surgery, indications for *3:* 392–393
Peptic ulcer, acute
treatment *3:* 394
Peptic ulcer, chronic
acid secretion *3:* 369
aetiology *3:* 369
air contrast radiography *3:* 371
aspirin consumption *3:* 370–371
corticosteroids *3:* 371
diagnosis *3:* 393
epidemiology *3:* 368
hydrogen ion diffusion, duodenal reflux gastritis and gastric ulcer *3:* 369–370
medical treatment *3:* 393–394
patho-physiology *3:* 369–371
site of *3:* 369
smoking *3:* 370–371
treatment *3:* 373–394
Pernicious anaemia
see anaemia, pernicious
Perphenazine
dosage relationships *4:* 339
schizophrenia, chronic
compared with thiothixene *4:* 115
structural formula *4:* 328
Pentose phosphate cycle
see hexose monophosphate shunt
Pethidine
analgesia, postoperative
compared with
methotrimeprazine *4:* 310–311
Petit mal
drug treatment *4:* 261
drugs of choice *4:* 261
ethosuximide *4:* 261
dosage and desirable plasma levels *4:* 262
paramethadione
dosage and desirable plasma levels *4:* 262
3/second generalised spike and wave *4:* 230
status epilepticus
diazepam *4:* 266
trimethadione
dosage and desirable plasma levels *4:* 262
Petit mal, centrencephalic
patho-physiology *4:* 233
Petit mal seizures
diazepam *3:* 453–454
Petit mal, status epilepticus
drug treatment *4:* 265
pH
cephalexin activity influenced by *3:* 44–48
pancuronium: precautions *4:* 220
Pharyngitis
antibacterial agents *4:* 138–139
diagnosis and treatment *3:* 460
Pharyngitis, acute
cephalexin *3:* 20
Pharyngitis, streptococcal
cephalexin
compared with
cyclacillin *2:* 23–24
phenoxymethylpenicillin *3:* 23–24
cyclacillin
compared with
cephalexin *3:* 23–24
drugs of choice *3:* 5
phenoxymethylpenicillin
compared with
cephalexin *3:* 23–24
Phenacemide
grand mal
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 244
pharmacokinetic properties *4:* 244
Phenelzine
dosage guide *4:* 378
structural formula *4:* 366
Phenethylbiguanide
see phenformin
Phenformin
absorption *3:* 103
adverse reactions *3:* 221–222
aerobic glycolysis inhibition *3:* 92
excretion *3:* 103
glucose, peripheral utilisation increase *3:* 92
half-life *3:* 103
hypoglycaemic activity characteristics *3:* 103
metabolism *3:* 103
pharmacokinetics *3:* 103
structural formula *3:* 99
Phenobarbital
see phenobarbitone
Phenobarbitone
breast milk *4:* 248
distribution *4:* 248
dosage guide *4:* 398
dosage: hypnotic *3:* 121
epilepsy: serum concentrations *3:* 428
excretion *4:* 248
grand mal
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 244, 248
interaction with
aminopyrine *4:* 278
DDT *4:* 278
dicoumarol *4:* 278
phenylbutazone *4:* 278
phenytoin *4:* 278
interactions *4:* 274–275
metabolism *3:* 121
mode of action *4:* 239–240, 242
pharmacological properties *4:* 394
pharmacokinetic properties *4:* 244, 248
phenytoin metabolism: influence on *4:* 272
phenytoin plasma levels, effect on *4:* 274–275
placental transfer *4:* 248
structural formula *4:* 390
Phenothiazine antipsychotics
structural formulae *4:* 390
Phenothiazine derivatives
acetophenazine *qv*
agranulocytosis *4:* 346

carphenazine *qv*
chlorpromazine *qv*
fluphenazine *qv*
intoxication in children *3:* 436
mesoridazine *qv*
perphenazine *qv*
pharmacological properties *4:* 394
prochlorperazine *qv*
structural formula *4:* 390
thiopropazate *qv*
trifulopromazine *qv*
Phenoxymethylpenicillin
adverse reactions *3:* 24
dosage
streptococcal pharyngitis *3:* 23
eosinophilia *3:* 24
streptococcal pharyngitis
compared with
cephalexin *3:* 23–24
failures *3:* 23–24
Phensuximide
half-life, plasma *4:* 245
pharmacokinetic properties *4:* 245
seizures, mixed
dosage and desirable plasma levels *4:* 262
see also succinimides
Phentermine
obesity *4:* 415
Phenurone
see phenacemide
L-Phenylalanine
structural formula *4:* 55
Phenylbutazone
osteoarthritis *3:* 132
interaction with
phenobarbitone *4:* 278
Phenylpiperazine derivatives
oxypertine *qv*
Phenyramidol
interaction with
phenytoin *4:* 276
Phenytoin
absorption *4:* 246
adverse reactions *3:* 428; *4:* 267–268
breast milk *4:* 248
cerebellar damage *4:* 270
chlordiazepoxide causing intoxication *3:* 259–260
diazepam causing intoxication *3:* 259–260
drug interactions *3:* 259–260
drug metabolism induction *4:* 271
dysmorphogenicity *4:* 269
epilepsy: serum concentrations *3:* 428
excretion *4:* 247
grand mal status epilepticus *4:* 265
half-life, plasma *4:* 244, 247
agents prolonging *4:* 276
interaction with
barbiturates *3:* 121
carbamazepine *4:* 278
chloramphenicol *4:* 276
DDT *4:* 276, 278
dicoumarol *4:* 276, 278
digitoxin *4:* 278
disulfiram *4:* 276
ethanol *4:* 278
isoniazid *4:* 276, 279
methylphenidate *4:* 276
metyrapone *4:* 278
phenobarbitone *4:* 278
phenyramidol *4:* 276
sulthiame *4:* 276
interactions *4:* 271–279
intoxication
ataxia *4:* 260
lethargy *4:* 260
nystagmus *4:* 260
related to blood levels *4:* 260
metabolism *4:* 247–248, 272
chlordane pre-treatment *4:* 272
DDT pre-treatment *4:* 272
inhibiting agents *4:* 273
3MC pre-treatment *4:* 272
phenobarbitone pre-treatment *4:* 272
metabolism effected by pre-treatment *4:* 272
mode of action *4:* 238–241
pharmacokinetic properties *4:* 244, 246–247
phenobarbitone effect on plasma levels *4:* 274–275
placental transfer *4:* 248*
plasma levels
drugs elevating *4:* 275–277, 279–280
toxicity symptoms *4:* 260, 263, 267
Phosphogluconate oxidative pathway
see hexose monophosphate shunt
Phosphorous depletion syndrome
antacid therapy complication *3:* 379
Physiotherapy
chronic bronchitis *4:* 83
Parkinsonism *4:* 71
Piles
sclerosant injection treatment *4:* 77
Pimozide
structural formula *4:* 329
Piperacetazine
dosage relationships *4:* 339
Piperidinediones
glutethimide *qv*
methyprylon *qv*
Pipradrol
dosage guide *4:* 378
structural formula *4:* 366
Pizotifen *3:* 159–203
absorption *3:* 194
adrenolytic activity *3:* 188–189
adverse reactions *3:* 176, 179–180; 196–198
antiarrhythmic activity *3:* 190–191
antibradykinin activity *3:* 188
anticholinergic activity *3:* 188
antidepressant activity *3:* 189–190
antihistaminic activity *3:* 187
antiserotonin activity *3:* 186–187
appetite increase *3:* 198
carbohydrate metabolism: effect on *3:* 191
cardiovascular haemodynamic effects *3:* 190
central nervous system sedative effects *3:* 189
contra-indications *3:* 200
dosage *3:* 197, 199, 200–201

headache, cluster *3:* 164–169, 180–181
migraine *3:* 157, 164–169, 172–175, 176–179
drug interactions *3:* 198, 200
dysmorphology studies *3:* 193–194
excretion *3:* 195
glyceryl trinitrate-induced headache: effect on *3:* 191–192
headache, cluster *3:* 164–165, 172–173, 180–181
headache, epileptic *3:* 166–167
headache, muscular contraction *3:* 166–167
headache, post-traumatic *3:* 166–167
headache, vascular *3:* 163–180
headache, vasomotor *3:* 166–167
hemicranicus, status *3:* 168–169
indications for use *3:* 196
migraine
compared with
dimethothiazine *3:* 201
methysergide *3:* 177–178
other prophylactic agents *3:* 175–178
placebo *3:* 172–175
serotonin antagonists *3:* 176–178
long-term studies *3:* 179–180
migraine, classic or common
therapeutic trials *3:* 156–157, 163–180
mode of action *3:* 182–186
neuralgia, facial *3:* 166–167
pharmacodynamic studies *3:* 182–194
pharmacokinetic studies *3:* 194–195
precautions in use *3:* 200
reproduction: effect on *3:* 193–194
serotonin relationship to migraine syndrome *3:* 184–185
structural formula *3:* 195
therapeutic trials *3:* 163–182
toxicology studies *3:* 192–193
weight gain *3:* 198–199

Placental transfer
cephalexin *3:* 59
diazepam *4:* 250
hypno-sedative drugs *3:* 120
pancuronium *4:* 209
phenobarbitone *4:* 248
phenytoin *4:* 248
thiopentone *3:* 120

Plasma
insulin transport *3:* 87

Pneumococcal pneumonia
drugs of choice *3:* 6

Pneumonia, primary atypical
drugs of choice *3:* 7

Pneumonias
antibacterial agents *4:* 138–139
cephalexin *3:* 15–19
drugs of choice *3:* 6

Podophyllin compound paint
condylomata, anal *4:* 79

Poisoning
phenothiazine intoxication in children *3:* 436

Poldine
duodenal ulcer *3:* 383

Poliomyelitis oral vaccine
administration with BCG and tetanus toxoid *3:* 290–291

Pollution, atmospheric
chronic bronchitis *4:* 81

Polycythaemia
development in chronic bronchitis *4:* 84

Polycythemia vera
drugs of choice *3:* 343–344
radioactive phosphorus ^{32}P *3:* 343
treatment schedules *3:* 343–344

Polymyxin B
in renal failure *3:* 264

Polypeptides
in renal failure *3:* 264

Polypharmacy
hypertension *4:* 93

Postmenopause
osteoporosis *4:* 108–110
primary hyperparathyroid treated with oestrogens *4:* 108–110

Potassium phenoxymethylpenicillin
streptococcal pharyngitis *3:* 5

Pre-cancer
cytotoxic therapy *3:* 286

Prednisolone
half-life, plasma *3:* 234
pharmacokinetics *3:* 234
protein binding *4:* 122
serum protein levels *4:* 122

Prednisone
acute lymphoblastic anaemia *3:* 336–337
adverse reactions *4:* 121–122
chronic lymphocytic leukaemia *3:* 339–340
glomerulonephritis: value in *3:* 283
nephrosis, childhood
compared with
cyclophosphamide *3:* 468–469
pharmacokinetics *3:* 234
protein binding *4:* 121–122
serum protein levels *4:* 121–122

Pregnancy
anticonvulsant drugs *4:* 269–270
cephalexin
adverse reactions *3:* 65
diabetes mellitus in *3:* 219
drug taking during *3:* 108–110
dysmorphology
prescribed medication *3:* 109–110
self medication *3:* 109–110
epileptic patients *3:* 108–109
glucose tolerance tests *3:* 207, 209
lithium *4:* 357
minocycline *3:* 325
nutritional deficiencies
dysmorphogenic effects *3:* 110
paramethadione *3:* 108–109
rubella vaccination to prevent infection in *3:* 128
syphilis
cephaloridine *3:* 40
thalidomide tragedy *3:* 108
trimethadione *3:* 108–109

Primidone
grand mal *4:* 264
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 244

metabolism *4:* 249
mode of action *4:* 242
pharmacokinetic properties *4:* 244, 249
Probenecid
cephalexin serum levels: effect on *3:* 55
+ cephalexin
gonorrhoea *3:* 37–39, 71
Probenecid-ampicillin
gonorrhoea: effective in males *3:* 292
Procainamide
ventricular arrhythmias *4:* 287
Procaine penicillin
streptococcal pharyngitis *3:* 5
Prochlorperazine
dosage relationships *4:* 339
structural formula *4:* 328
Proctitis
management of *4:* 80
sulphasalazine *4:* 80
Procto-colitis
management of *4:* 80
sulphasalazine *4:* 80
Pro-insulin
insulin precursor *3:* 87, 88
Prolapse pile
rubber ring ligation *4:* 77
Prolapse, rectal complete
management of *4:* 79
Prolapse, rectal mucosa
management in the elderly *4:* 79
rubber ring ligation *4:* 77
Propantheline
duodenal ulcer *3:* 383
Prostaglandins
migraine: role in *3:* 156
Protein
diabetes mellitus dietary management *3:* 211
glucose source *3:* 84
Protein binding
ampicillin *3:* 58, 59
azathioprine *3:* 234
cephalexin *3:* 58, 59
cephaloridine *3:* 58, 59
cephalothin *3:* 58, 59
chlorpromazine *4:* 333
cyclophosphamide *3:* 234
desipramine *4:* 370
epicillin *3:* 318
hypno-sedative drugs *3:* 120
6-mercaptopurine *3:* 234
methotrexate *3:* 234
neuromuscular blocking agents *4:* 156
prednisolone *4:* 122
prednisone *4:* 121–122
sulphonylureas *3:* 100
Protein metabolism
doxycycline *4:* 429–430
oxytetracycline *4:* 429–430
Protein, serum
pancuronium blockade: effect on *4:* 206
Protein synthesis
pathway *3:* 230
Protein, urinary
cephalexin may cause false reading *3:* 70
Proteus mirabilis
cephalexin sensitivity *in vitro 3:* 45–47
Proteus spp.
cephalexin sensitivity *in vitro 3:* 46
Protriptyline
dosage guide *4:* 378
structural formula *4:* 366
Pruritus ani
and erythrasma *4:* 107–108
Pseudoephedrine
vasomotor rhinitis *3:* 429
Pseudomonas aeruginosa
cephalexin sensitivity *in vitro 3:* 45–46
Psoriasis
associated diseases *4:* 86
classification *4:* 86
corticosteroid therapy, intralesional *4:* 88
corticosteroid therapy, systemic *4:* 88
tetracosactrin depot *4:* 88
corticosteroid therapy, topical *4:* 87
cytotoxic drugs, systemic therapy *4:* 87–88
dietary factors *4:* 89
dietary regimen *4:* 307–308
Goeckerman regimen, modified *4:* 87
incidence *4:* 85
Leeds technique *4:* 87
methotrexate *4:* 87–88
liver damage *3:* 267–268
nature and treatment *4:* 85–89
pathogenesis *4:* 85
treatment, local *4:* 86–87
treatment, oral and systemic *4:* 86
turkey meat diet *4:* 307–308
Psychiatric reactions
levodopa *4:* 63, 65
Psychoactive ions
rubidium – the next? *4:* 357
Psychoses
associated with old age
psychotherapeutic drugs *4:* 402–403
children
diagnostic difficulties *4:* 400
Psychoses, functional
antipsychotic drugs *4:* 335–336
Psychosis, acute toxic
amantadine overdosage *3:* 436
Psychosis, manic-depressive
maintenance therapy
lithium *4:* 350
manic phase
chlorpromazine *4:* 349
lithium *4:* 439
Psychotherapeutic drugs
see psychotropic drugs
Psychotropic drugs
antianxiety drugs *qv*
antidepressant drugs *qv*
children *4:* 400–402
clinical trials, controlled *4:* 325
clinical use of *4:* 321–360, 361–410
confounding variables *4:* 325

contra-indications *4:* 402
depression of childhood *4:* 400–401
depressive reactions *4:* 362–365
diagnoses uncertain *4:* 324–325
hyperkinetic children *4:* 401
the impact of *4:* 322–323
lithium *qv*
mental deficiency *4:* 403
limitations of drug therapy *4:* 403
nomenclature *4:* 323–324
Parkinsonism *4:* 70
pathogenesis *4:* 324–325
psychoses associated with old age *4:* 402–403
schizophrenia, childhood *4:* 400–401
special problems in evaluation *4:* 324–325
use: special clinical problems *4:* 400–407
Pteroic acid
see folic acid
Pterylglutamic acid
see folic acid
Pulmonary abnormalities
see lung abnormalities
Pulmonary, embolism
see embolism, pulmonary
Pulmonary fibrosis
see fibrosis, pulmonary
Pulmonary hypertension
see hypertension, pulmonary
Purpura, 'refractory' thrombocytopenic
cyclophosphamide *3:* 288
Pus
cephalexin concentration *3:* 59
Pyelonephritis
ampicillin *3:* 31
cephalexin *3:* 29
Pyrimidines, halogenated
cytological effects *3:* 245
metabolic effects *3:* 245
pharmacokinetics *3:* 244–245
PZI
see insulin, protamine zinc

Q

Quinalbarbitone
dosage: hypnotic *3:* 121
metabolism *3:* 121
Quinazolones
methaqualone *qv*

R

Radiography, air contrast
peptic ulcer diagnosis *3:* 371
Radioimmunoassay
digoxin serum levels *3:* 115
Radiology
kidney and contrast media *3:* 116
lung abnormalities
nitrofurantoin *3:* 112–113
nitrofurantoin causing lung abnormalities *3:* 112–113
Rauwolfia alkaloids
reserpine *qv*
Renal disease
hypertension mechanism *3:* 274–275
hypoglycaemic agents, oral *3:* 220
levodopa pharmacokinetics, influence on *4:* 59–60
pancuronium: precautions *4:* 219–220
Renal disorders
rheumatoid arthritis *4:* 125
Renal dysfunction
antibacterial agents host determinants *4:* 141
Renal failure
see failure, renal
Renal function, impairment
cephalexin half-life, serum *3:* 53
Renal function, normal
antibacterial agents *3:* 262–263
Renal insufficiency
digitalis dosage *3:* 259
Renin activity
contraceptives, oral cause increase *3:* 111–112
Reproduction
cytotoxic drugs effect on *3:* 359–362
lactulose effect on *4:* 42
Reserpine
hypertension *4:* 94, 96–97
structural formula *4:* 326
Respiration
pancuronium effect on *4:* 205
Respiratory depression
hypno-sedative drugs *3:* 119
Respiratory tract infections
epicillin *3:* 318
see lower respiratory tract infections
see upper respiratory tract infections
Reticulum cell sarcoma
see sarcoma, reticulum cell
Rheumatic disorders
immunosuppressive drugs *3:* 129–131
see also arthritis, rheumatoid
Rheumatoid arthritis
see arthritis, rheumatoid
Rhinitis, vasomotor
pseudoephedrine *3:* 429
Rhinosinusitis, acute
cehalexin *3:* 20, 21
Ribonucleic acid
see RNA
Rifamide
in renal failure *3:* 265
Rifampicin
adverse reactions *3:* 440
in renal failure *3:* 265
Rigidity
management with diazepam *3:* 123
RNA
cell proliferation *3:* 229–231
synthesis *3:* 230–231
Rubella
immunisation *4:* 111–113
vaccination strategy *3:* 128
vaccination to prevent infection in pregnancy *3:* 128
Rubella vaccine
myeloradiculoneuritis *4:* 112–113
Rubidium
the next psychoactive ion? *4:* 357

S

Salicylates
  gastric mucosa effects as seen by camera *3:* 443
Salmonella spp.
  cephalexin sensitivity *in vitro 3:* 45, 47
Sandomigran
  see pizotifen
Sansert
  see methysergide
Sarcoma, reticulum cell
  chlorambucil *3:* 341
  methotrexate *3:* 341
  nitrogen mustard *3:* 341
  prognosis *3:* 135–136
  radiotherapy *3:* 136
  treatment schedules *3:* 341
  vincristine *3:* 341
Scarlet fever
  cephalexin *3:* 21–22
Schizo-affective disorder, excited
  chlorpromazine *4:* 351
  lithum *4:* 350–351
Schizophrenia
  antipsychotic drugs *4:* 334–335
  chlorpromazine, altered dosage schedules *3:* 456
  classification *4:* 337–338
  fluphenazine *4:* 308–309, 340
  lithium *4:* 35
  maintenance therapy *4:* 115–116, 340
  trifluoroperazine, altered dosage schedules *3:* 456
Schizophrenia, childhood
  psychotherapeutic drugs *4:* 400–401
Schizophrenia, chronic
  maintenance therapy
    perphenazine compared with
      thiothixene *4:* 115
    thiothixene compared with
      perphenazine *4:* 115
Sclerosing agent
  piles *4:* 77
Sedation
  hypno-sedative drugs *3:* 119
  peptic ulcer management *3:* 392
Sedative drugs
  therapeutic goal *3:* 118
  withdrawal reactions *4:* 406
  see also hypno-sedative drugs
Sedative-hypnotics
  clinical pharmacology *3:* 118–123
  see also hypno-sedative drugs
Seizure focus, strength
  patho-physiology *4:* 236–237
Seizures, cortical diffuse
  patho-physiology *4:* 234
Seizures, focal
  drugs of choice *4:* 263
  patho-physiology *4:* 234–235
  spike and wave activity *4:* 231
  see also epilepsies, focal
  see also grand mal
Seizures, focal, status
  drug treatment *4:* 265
Seizures, minor motor
  ACTH *4:* 264–265
    dosage and desirable plasma levels *4:* 262
  diazepam *4:* 265
    dosage and desirable plasma levels *4:* 262
  drug treatment *4:* 264–265
  nitrazepam *4:* 265
    dosage and desirable plasma levels *4:* 262
Seizures, mixed
  methsuximide
    dosage and desirable plasma levels *4:* 262
  phensuximide
    dosage and desirable plasma levels *4:* 262
Seminoma
  alkylating agents *3:* 345
Septicaemias
  antibacterial agents *4:* 138–139
  benzylpenicillin + cephalexin *3:* 41
  cephalexin *3:* 41
    + benzylpenicillin *3:* 41
    failures *3:* 41
  with coagulation disseminated intravascular
    heparin *3:* 134
  drugs of choice *3:* 6
Serotonin
  migraine: role in *3:* 154, 182–183
  see also monoamines
Serotonin antagonists
  methysergide *qv*
  see also antiserotonin agents
Serum
  cephalexin activity influenced by *3:* 44–48
Serum protein levels
  prednisolone *4:* 122
  prednisone *4:* 121–122
Sex
  drug metabolism: effect of *3:* 295
SGOT
  see transaminases, serum
SGPT
  see transaminases, serum
Shigella dysenteriae
  cephalexin sensitivity *in vitro 3:* 47
Shock, cardiogenic
  treatment of *4:* 288
Side-effects
  see drug reactions, adverse
Silicone
  osteoarthritis joint lubricant *3:* 288–289
Skeletal muscles
  pancuronium effect on *4:* 190–191
Skin infections
  cephalexin *3:* 33–34, 35
    bacteriological results *3:* 35
    clinical results *3:* 35
    efficacy *3:* 35
Skin lesions
  topical cytotoxic drug therapy *3:*
    347
Sleep
  quality *4:* 290–291
  lack of
    see insomnia

Smoking
chronic bronchitis, relationship to *4:* 81
peptic ulcer *3:* 370–371, 374
SN263
peptic ulcer *3:* 390
Sodium bicarbonate ear drops BPC
ear wax solvent efficacy *3:* 125
Sodium toxicity
antacid therapy complication *3:* 378
Soft tissue infections
cephalexin *3:* 33–34, 35
bacteriological results *3:* 35
clinical results *3:* 35
efficacy *3:* 35
Sorbitol
dosage *4:* 18
encephalopathy, portal systemic
compared with lactulose *4:* 18–19
Spasticity
management with diazepam *3:* 123
Spectinomycin
absorption and excretion *3:* 326
adverse reactions *3:* 328
antibacterial activity *3:* 326
dosage *3:* 326, 327, 328
gonorrhoea *3:* 326–328
pharmacokinetics *3:* 326
structural formula *3:* 327
therapeutic trials *3:* 326–328
Spironolactone
contraceptives, oral
hypertension control *3:* 111
hypertension control *4:* 94–96
contraceptives, oral *3:* 111
oestrogens, conjugated *3:* 111
oestrogens, conjugated
hypertension control *3:* 111
Staphylococcal infections
drugs of choice *3:* 6
experimentally-induced
cephalexin *3:* 49–50
penicillin resistance *3:* 6
cephalexin *3:* 42–43
see also penicillin-resistant infections
Staphylococcus aureus
cephalexin sensitivity *in vitro 3:* 45, 47
Staphylococcus coagulase positive
cephalexin sensitivity *in vitro 3:* 45
Steatorrhoea
triglycerides, medium chain *3:* 124
Stenosis, pyloric
anticholinergics contra-indicated *3:* 382
Sterility
cytotoxic drugs *3:* 359–360
Stomach emptying
metoclopramide *3:* 295–296
Streptococcal infections
experimentally induced
cephalexin *3:* 50
Streptococcus faecalis
cephalexin sensitivity *in vitro 3:* 45, 47
Streptococcus group A
cephalexin sensitivity *in vitro 3:* 45
Streptococcus pyogenes
cephalexin sensitivity *in vitro 3:* 47
Streptokinase
myocardial infarction *3:*
451–452
compared with heparin *3:* 450–451
pulmonary embolism
compared with heparin *3:* 280
Streptomycin
antibacterial activity *in vitro 3:* 317
in renal failure *3:* 264
Stroke
antihypertensive therapy *3:* 452–453
and hypertension *3:* 452–453
Succinimides
mode of action *4:* 243
Succinylcholine
see suxamethonium
Sulphadimidine
in renal failure *3:* 265
Sulphafurazole
in renal failure *3:* 264
Sulphamethoxazole
in renal failure *3:* 265
Sulphamethoxazole + trimethoprim
see co-trimoxazole
Sulphanilamide
antimicrobial activity *3:* 1–2
Sulphasalazine
proctitis and procto-colitis *4:* 80
Sulphonamides
sulphonylureas *qv*
urinary tract infections
compared with
cephalexin *3:* 31–32
primary treatment *3:* 416
Sulphonylureas
adverse reactions *3:* 220–221
dosage *3:* 100
drug interactions *3:* 224–225
excretion *3:* 100
hypoglycaemic activity characteristics *3:*
100–103
hypoglycaemic effect
insulin synergy *3:* 91
metabolism *3:* 100
mode of action *3:* 88–91
hepatic glucose release inhibition *3:* 90
pancreas β-cell stimulation *3:* 89–90
peripheral effects *3:* 91
pharmacokinetics *3:* 100–103
protein binding *3:* 100
structural formulae *3:* 99
Sulthiame
grand mal
dosage and desirable plasma levels *4:* 262
half-life, plasma *4:* 245, 251
interaction with
phenytoin *4:* 276
mode of action *4:* 243
pharmacokinetic properties *4:* 245, 250–251
Superinfections
cephalexin *3:* 69

Surgery
halothane: unintended exposure *4:* 105–107
obesity management *4:* 416
peptic ulcer: indications for *3:* 392–393
Surgery, pelvic
thrombosis: prevention by dextran 70 *4:* 117–118
Surgery, stereotactic
Parkinsonism *4:* 71
Suxamethonium
intubation
compared with
pancuronium *4:* 184
prior administration to pancuronium *4:* 198
rational use of *4:* 153–157
Sympathomimetic stimulants
dosage guide *4:* 378
structural formulae *4:* 366
Syphilis
cephalexin *3:* 37, 40
failures *3:* 40
cephaloridine
pregnancy *3:* 40
pregnancy
cephaloridine *3:* 40

T

$T_{½}$
see half-life, plasma
Tachycardia, ventricular
example of *4:* 286
TBDC
total body digoxin concentration
Tegretol
see carbamazepine
Teratogenicity
see dysmorphology
Testape
diabetes mellitus urine testing *3:* 212
Tetanus toxoid
administration with BCG and oral poliomyelitis vaccines *3:* 290–291
Tetracosactrin depot
psoriasis *4:* 88
Tetracyclines
antibacterial activity *3:* 321
antibacterial activity *in vitro 3:* 317
bronchitis chronic *4:* 82
acute exacerbations of *3:* 6
bronchitis, purulent *3:* 6
excretion rate *3:* 323
in renal failure *3:* 264; *4:* 427–428
structural formula *3:* 320
urinary tract infection
primary treatment *3:* 416
Tetrobenazine
structural formula *4:* 326
Thalidomide
dysmorphogenicity *3:* 108, 434–435
in pregnancy *3:* 108
Thiazides
hypertension control *4:* 94–96
Thiethylperazine
prevention of postoperative vomiting *3:* 278
Thiobarbiturates
methohexitone *qv*
thiopentone *qv*
Thiohexitone
metabolism *3:* 121
Thiopentone
dosage: hypnotic *3:* 121
hypnotic action, function of dose *3:* 120
metabolism *3:* 121
placental transfer *3:* 120
Thiopropazate
dosage relationships *4:* 339
structural formula *4:* 328
Thiopurines
cytological effects *3:* 246
mode of action *3:* 235
molecular effects *3:* 246–247
pharmacokinetics *3:* 245–246
Thioridazine
dosage relationships *4:* 339
Thio-TEPA
ovarian carcinoma *3:* 345
pharmacokinetics *3:* 235
Thiothixene
dosage relationships *4:* 339
schizophrenia, chronic
compared with perphenazine *4:* 115
structural formula *4:* 326
Thioxanthene derivatives
chlorprothixene *qv*
thiothixene *qv*
Throat infections in children
diagnosis and treatment *3:* 460
Thromboembolism, arterial
contraceptives, oral *4:* 300–301
Thromboembolism, venous
contraceptives, oral *4:* 300–301
Thrombolytic therapy
myocardial infarction *3:* 450–451
Thrombosis
prevention after pelvic surgery
dextran 70 *4:* 117–118
Thrombosis in femoral neck fractures, prophylaxis
dextran 70 compared with
dicoumarol *4:* 116–117
dicoumarol compared with
dextran 70 *4:* 116–117
Thyroid 'C'
see calcitonin
Thyroid enlargement
lithium *4:* 355–356
Thyroid function
hypoglycaemic agents, oral effect *3:* 94
Thyroid suppressibility
antithyroid treatment assessment *3:* 445–447
Tolazamide
absorption *3:* 102
dosage *3:* 100
excretion *3:* 102
half-life *3:* 100, 102
hypoglycaemic activity characteristics *3:* 100, 102
metabolism *3:* 102
metabolites *3:* 102

mode of action *3:* 89
pharmacokinetics *3:* 100, 102
structure *3:* 99
Tolbutamide
absorption *3:* 101
cardiovascular disease *3:* 222–224
dosage *3:* 100
excretion *3:* 101
half-life *3:* 100, 101
hypoglycaemic activity characteristics *3:* 100, 101
metabolites *3:* 101
mode of action *3:* 89
hepatic glucose release inhibition *3:* 90
pharmacokinetics *3:* 100–101
structure *3:* 99
Tonsillitis, acute
cephalexin *3:* 21–22
Tonsillitis, acute follicular
cephalexin *3:* 21
Tonsillar infections, acute
cephalexin *3:* 20–21
Tranylcypromine
adverse reactions *4:* 386
dosage guide *4:* 378
structural formula *4:* 366
Tranexamic acid
management of ruptured intracranial aneurysms *4:* 114
Tranquillisers
compared with
hypno-sedative drugs *3:* 118–119
pharmacodynamics *3:* 119
Transaminases, serum
cephalexin *3:* 65–66
Transplantation, renal
co-trimoxazole and associated leucopenia *4:* 127–128
Triamcinolone acetonide
dermo-jet injection
severe nail dystrophy *4:* 307
Tricarboxylic acid cycle
see citric acid cycle
Trichlorofluoromethane
blood levels following inhalation *3:* 430
Trichomoniasis
diagnosis *4:* 422
treatment *4:* 424–425
Tricyclamol
duodenal ulcer *3:* 383
Tricyclic antidepressants
see antidepressants, tricyclic
Tridione
see trimethadione
Triethylene thiophosphoramide
see thio-TEPA
Trifluoperazine
dosage guide *4:* 398
dosage relationships *4:* 339
schizophrenia improved under altered dosage schedules *3:* 456
structural formula *4:* 390
Trifluperidol
structural formula *4:* 329
Trifluopromazine
dosage relationships *4:* 339
structural formula *4:* 328
Triglycerides, medium chain
absorption *3:* 124
hyperchylomicronaemia *3:* 124
lymphangiectasia, intestinal *3:* 124
paediatrics *3:* 124–125
steatorrhoea *3:* 124
Triglyde
see triglycerides, medium chain
Trimethadione
dysmorphology *3:* 108–109
epileptic pregnant patients
dysmorphology *3:* 109
half-life, plasma *4:* 245, 249
metabolism *4:* 249
mode of action *4:* 239–240, 242–243
petit mal
dosage and desirable plasma levels *4:* 262
pharmacokinetic properties *4:* 245, 249
pregnancy *3:* 108–109
Trimethoprim-sulphamethoxazole
see co-trimoxazole
Trimipramine
dosage guide *4:* 378
structural formula *4:* 366
Trobicin
see spectinomycin
Troxidone
see trimethadione
Tryptanol
see amitriptyline
d-Tubocurarine
adverse reactions *4:* 189
blockade reversal
compared with
pancuronium *4:* 188–189
cardiovascular effects
compared with
pancuronium *4:* 186–187
dose-response curve *4:* 197
duration of action
compared with
pancuronium *4:* 187–188
intubation
compared with
pancuronium *4:* 184–186
onset of action
compared with
pancuronium *4:* 183–184
potency in conscious subjects
compared with
alcuronium *4:* 196
pancuronium *4:* 196
Tubular secretion
cephalexin *3:* 60–62
Tumour cell kinetics *3:* 334–335
Tumours
resistance to therapy *3:* 363–364
Tumours, malignant
cytotoxic drugs *3:* 362–363
therapeutic immunosuppression *3:* 362–363

Tumours, rectal
management of *4:* 80
Turkey meat
psoriasis: dietary regimen *4:* 307–308
Tybamate
dosage guide *4:* 398
pharmacological properties *4:* 394
structural formula *4:* 390
Typhoid fever
co-trimoxazole *4:* 113–114
Tyramine
migraine: role in *3:* 155
L-Tyrosine
structural formula *4:* 55

U

Ulcerative colitis
see colitis, ulcerative
Upper respiratory tract infections
cephalexin *3:* 19–24
bacteriological results *3:* 19–20
comparative trials *3:* 21–24
non-comparative trials *3:* 21
therapeutic results *3:* 19–20
paediatrics
cephalexin *3:* 36
Upper respiratory tract infections, acute
bacterial otitis media a complication in infants and young children
drug of choice *3:* 6
Urate pool
gout *3:* 422–423
Urethritis, non-specific
antibacterial agents *4:* 138–139
Urinary tract infection
ampicillin *3:* 416
compared with
cephalexin *3:* 29–32
failures *3:* 30
recurrence *3:* 30
antibacterial agents *4:* 138–139
primary treatment *3:* 415–416
cephalexin *3:* 7, 24–33
bacteriological results *3:* 25–27
clinical results *3:* 25–27
comparative trials *3:* 28–33
compared with
ampicillin *3:* 29–32
cephaloridine *3:* 31–32
nitrofurantoin *3:* 31–32
other cephalosporins *3:* 28–29
sulphonamides *3:* 31–32
failures *3:* 30
follow-up *3:* 25
non-comparative trials *3:* 24–27
recurrence *3:* 30
cephaloglycin
compared with
cephalexin *3:* 28–29
cephaloridine
compared with
cephalexin *3:* 28–29, 31–32
cephalothin
compared with
cephalexin *3:* 28–29
co-trimoxazole *3:* 416
diagnosis and treatment *3:* 414–417
nalidixic acid *3:* 416
nitrofurantoin *3:* 416
compared with
cephalexin *3:* 31–32
paediatrics
cephalexin *3:* 36
re-infection *3:* 415
sulphonamides *3:* 416
tetracyclines *3:* 416
Urine testing
diabetes mellitus *3:* 212
Urography
renal failure caused by media *3:* 116

V

Vaginal inflammations
treatment *4:* 425
Vaginitis
candidiasis *4:* 421–422
diagnosis and treatment *3:* 461–462; *4:* 419–425
diagnosis: clinical aspects *4:* 419–420
diagnosis: differential *4:* 421–424
diagnosis: laboratory *4:* 420–421
Haemophilus vaginalis 4: 423
metronidazole *3:* 461
trichomoniasis *4:* 422
Vaginitis, atrophic
diagnosis *4:* 423
treatment *4:* 425
Vaginitis, chemical
diagnosis *4:* 422–423
Vaginitis, non specific
diagnosis *4:* 423
Vagotomy
insulin secretion: effect on *3:* 86
Valium
see diazepam
Vancomycin
in renal failure *3:* 264
Vascular incidents
contraceptives, oral *4:* 300–301
Vasodilators, systemic
glaucoma *3:* 467–468
Venereal disease
cephalexin *3:* 36–40
bacteriological results *3:* 37–40
clinical results *3:* 37–40
see also gonorrhoea
syphilis
Ventilation
pancuronium blockade: effect on *4:* 206–207
Ventricular ectopic beat
example of *4:* 286
Ventricular fibrillation
see fibrillation, ventricular
Ventricular tachycardia
see tachycardia, ventricular

Vestibular function modification
betahistine hydrochloride *4:* 120–121
Vinblastine
mode of action *3:* 235
pharmacokinetics *3:* 234
Vinca alkaloids
cytological effects *3:* 240
mode of action *3:* 234
molecular effects *3:* 240–241
pharmacokinetics *3:* 234–240
Vincristine
acute lymphoblastic leukaemia *3:* 336–337
mode of action *3:* 235
neurotoxicity *3:* 358
pharmacokinetics *3:* 234
reticulum cell sarcoma *3:* 341
Vitamin B_{12}
pancreatic insufficiency causing malabsorption *3:* 287
Vomiting, postoperative
prevention of *3:* 278
thiethylperazine *3:* 278

W
Warfarin
interaction with carbamazepine *4:* 278
Warts
see condylomata, anal
Waxsol
composition *3:* 125
ear wax solvent efficacy *3:* 125
Weight gain
pizotifen *3:* 198–199
Weight reduction *4:* 412–413
Wilms' tumour
actinomycin D *3:* 346

X
Xerumenex
composition *3:* 125
ear wax solvent efficacy *3:* 125

Z
Zarotin
see ethosuximide

Vol. 3, 1972

Drugs

International Journal of Current Therapeutics and Applied Pharmacology Reviews, featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts

Editor *G.S. Avery*

Associate Editors *R.N. Brogden*, *D.N. McDonald*, *Denise W. Rofe*, *T.M. Speight*

Assistant Editor *I.W. Davey*

Chief Consulting Editor *G.S. McL. Kellaway*

Consulting Editors

T.F. Acheson, Sydney
J.W. Ardagh, Christchurch
J.A. Baird, Wellington
Sir Brian Barratt-Boyes, Auckland
R.W. Beal, Adelaide
D.W. Beaven, Christchurch
R.F.A. Becke, Sydney
D.G. Bonham, Auckland
J.S. Boyd-Wilson, Wellington
E.P. Brasted, Auckland
J.G. Buchanan, Auckland
R. Carruthers, Launceston
D.S. Cole, Auckland
W.H.J. Cole, Melbourne
J.F. Copplestone, Geneva
J.M. Court, Melbourne
L.W. Cox, Adelaide
Marion D. Cridland, Sydney
J.A.K. Cuningham, Christchurch
M.H.L. de Groot, Toowoomba
I.S. de la Lande, Adelaide
P.B. Doak, Auckland
A.E. Doyle, Melbourne
Keitha Farmer, Auckland
T. Gebbie, Wellington
G.H. Green, Auckland
D.R. Hay, Christchurch
P.B. Herdson, Auckland
G.C. Hitchcock, Auckland
F.C. Hollows, Sydney
C. McK. Holmes, Dunedin
W.R. Holmes, Christchurch
H.K. Ibbertson, Auckland
C.T. Jones, Auckland
Priscilla Kincaid-Smith, Melbourne
J.W. Lance, Sydney
J.H. Lee, Sydney
A.W. Liley, Auckland
P.J. Little, Christchurch
A.D. Macalister, Dunedin
J.B. Mackay, Wellington
E.G. McQueen, Dunedin
G. Milner, Canberra
J.D.K. North, Auckland
K.P. O'Brien, Auckland
R.G. Park, Wellington
D.W. Piper, Sydney
W.M. Platts, Christchurch
D.E. Poswillo, London
M.J. Rand, Melbourne
P.C. Reade, Melbourne
R.G. Robinson, Sydney
B.S. Rose, Rotorua
W.S. Rose, Brisbane
N. Roydhouse, Auckland
M.J.W. Sando, Adelaide
R.J. Seddon, Auckland
F.O. Simpson, Dunedin
B.N. Singh, Auckland
J.G. Sloman, Melbourne
B.C. Stratford, Melbourne
P. Taft, Melbourne
J. Tonkin, Sydney
J.H. Tyrer, Brisbane
A.M.O. Veale, Dunedin
D.N. Wade, Sydney
J.M. Watt, Dunedin
F.A. Whitlock, Brisbane

S. Karger · Basel · München · Paris · London · New York · Sydney
Australasian Drug Information Services Pty. Ltd. · Sydney

S. Karger · Basel · München · Paris · London · New York · Sydney
Arnold-Böcklin-Strasse 25, CH–4000 Basel 11 (Switzerland)
Australasian Drug Information Services Pty. Ltd., P.O. Box 194,
Balgowlah/Sydney, NSW 2093 (Australia)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

© Copyright 1972 by Australasian Drug Information Services Pty. Limited, Sydney
Printed in Switzerland by Thür Offsetdruck, Birsfelden

Contents

Guest Editorials

Anthony, M. and Lance, J.W. (Sydney): Current Concepts in the Pathogenesis and Interval Treatment of Migraine 153

Finland, M. (Boston): Oral and Parenteral Cephalosporins: The Place of Cephalexin in Antibacterial Therapy 1

Evaluations on New Drugs

Brogden, R.N. and Avery, G.S. (Auckland): New Antibiotics: Epicillin, Minocycline and Spectinomycin. A summary of their antibacterial activity, pharmacokinetic properties and therapeutic efficacy 314

Speight, T.M. and Avery, G.S. (Auckland): Pizotifen (BC 105): A Review of its Pharmacological Properties and Therapeutic Efficacy in Vascular Headaches 159

Speight, T.M.; Brogden, R.N., and Avery, G.S. (Auckland): Cephalexin: A Review of its Antibacterial, Pharmacological and Therapeutic Properties 9

Review Articles

Breidahl, H.D.; Ennis, G.C.; Martin, F.I.R.; Stawell, J.R., and Taft, P. (Melbourne): Insulin and Oral Hypoglycaemic Agents I: Physiological and Clinical Pharmacological Aspects 79

Breidahl, H.D.; Ennis, G.C.; Martin, F.I.R.; Stawell, J.R., and Taft, P. (Melbourne): Insulin and Oral Hypoglycaemic Agents II: Clinical and Therapeutic Aspects 204

Chalmers, A.H.; Burgoyne, L.A., and Murray, A.W. (Adelaide): Antineoplastic and Immunosuppressive Drugs I: Biochemical and Clinical Pharmacological Considerations 227

Cridland, Marion D. (Sydney): Antineoplastic and Immunosuppressive Drugs II: Therapeutic Uses 331

Cridland, Marion D. (Sydney): Antineoplastic and Immunosuppressive Drugs III: Adverse Effects and Therapeutic Problems 352

Piper, D.W. and Heap, T.R. (Sydney): Medical Management of Peptic Ulcer. With reference to anti-ulcer agents in other gastrointestinal diseases 366

Special Article

Sir Derrick Dunlop (Edinburgh): Medicines, Governments and Doctors 305

Practical Therapeutics

Friedlander, D.H. (Hamilton): A Guide to Safe and Effective Digitalis Therapy . . . 404

Little, P.J. (Christchurch): Diagnosis and Treatment of Urinary Tract Infection . . . 414

Robinson, R.G. and Corrigan, A.B. (Sydney): Management of Gout 422

Roydhouse, N. (Auckland): Management of Otitis Media in General Practice 418

Drug Literature Abstracts 108, 254, 427

Subject Index 137, 297, 471

Vol. 4, 1972

Drugs

International Journal of Current Therapeutics and Applied Pharmacology Reviews, featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts

Editor *G.S. Avery*

Associate Editors *R.N. Brogden*, *D.N. McDonald*, *Denise W. Rofe*, *T.M. Speight*

Assistant Editor *I.W. Davey*

Chief Consulting Editor *G.S. McL. Kellaway*

Consulting Editors

T.F. Acheson, Sydney
J.W. Ardagh, Christchurch
J.A. Baird, Wellington
Sir Brian Barratt-Boyes, Auckland
R.W. Beal, Adelaide
D.W. Beaven, Christchurch
R.F.A. Becke, Sydney
D.G. Bonham, Auckland
J.S. Boyd-Wilson, Wellington
E.P. Brasted, Auckland
J.G. Buchanan, Auckland
R. Carruthers, Launceston
D.S. Cole, Auckland
W.H.J. Cole, Melbourne
J.F. Copplestone, Geneva
J.M. Court, Melbourne
L.W. Cox, Adelaide
Marion D. Cridland, Sydney
J.A.K. Cuningham, Christchurch
M.H.L. de Groot, Toowoomba
I.S. de la Lande, Adelaide
P.B. Doak, Auckland
A.E. Doyle, Melbourne
Keitha Farmer, Auckland
T. Gebbie, Wellington
G.H. Green, Auckland
D.R. Hay, Christchurch
P.B. Herdson, Auckland
G.C. Hitchcock, Auckland
F.C. Hollows, Sydney
C. McK. Holmes, Dunedin
W.R. Holmes, Christchurch
H.K. Ibbertson, Auckland
C.T. Jones, Auckland
Priscilla Kincaid-Smith, Melbourne
J.W. Lance, Sydney
J.H. Lee, Sydney
A.W. Liley, Auckland
P.J. Little, Christchurch
A.D. Macalister, Dunedin
J.B. Mackay, Wellington
E.G. McQueen, Dunedin
G. Milner, Canberra
J.D.K. North, Auckland
K.P. O'Brien, Auckland
R.G. Park, Wellington
D.W. Piper, Sydney
W.M. Platts, Christchurch
D.E. Poswillo, London
M.J. Rand, Melbourne
P.C. Reade, Melbourne
R.G. Robinson, Sydney
B.S. Rose, Rotorua
W.S. Rose, Brisbane
N. Roydhouse, Auckland
M.J.W. Sando, Adelaide
R.J. Seddon, Auckland
F.O. Simpson, Dunedin
B.N. Singh, Auckland
J.G. Sloman, Melbourne
B.C. Stratford, Melbourne
P. Taft, Melbourne
J. Tonkin, Sydney
J.H. Tyrer, Brisbane
A.M.O. Veale, Dunedin
D.N. Wade, Sydney
J.M. Watt, Dunedin
F.A. Whitlock, Brisbane

S. Karger · Basel · München · Paris · London · New York · Sydney
Australasian Drug Information Services Pty. Ltd. · Sydney

S. Karger · Basel · München · Paris · London · New York · Sydney
Arnold-Böcklin-Strasse 25, CH–4000 Basel 11 (Switzerland)
Australasian Drug Information Services Pty. Ltd., P.O. Box 194,
Balgowlah/Sydney, NSW 2093 (Australia)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

© Copyright 1972 by Australasian Drug Information Services Pty. Limited, Sydney
Printed in Switzerland by Thür Offsetdruck, Birsfelden

Contents

Guest Editorials

Bircher, J. (Berne): The Many Effects of Lactulose: A Rational Approach to Its Therapeutic Use 1

Conn, H.O. (New Haven): Interactions of Lactulose and Neomycin 4

Foldes, F.F. (Bronx, NY): The Rational Use of Neuromuscular Blocking Agents: The Role of Pancuronium 153

Evaluations on New Drugs

Avery, G.S.; Davies, Elizabeth F. and Brogden, R.N. (Auckland): Lactulose: A Review of its Therapeutic and Pharmacological Properties with particular reference to ammonia metabolism and its mode of action in portal systemic encephalopathy 7

Speight, T.M. and Avery, G.S. (Auckland): Pancuronium Bromide: A Review of its Pharmacological Properties and Clinical Application 163

Review Articles

Calne, D.B. and Reid, J.L. (London): Antiparkinsonian Drugs: Pharmacological and Therapeutic Aspects 49

Hollister, L.E. (Palo Alto, Calif.): Clinical Use of Psychotherapeutic Drugs I: Antipsychotic and Antimanic Drugs 321

Hollister, L.E. (Palo Alto, Calif.): Clinical Use of Psychotherapeutic Drugs II: Antidepressant and Antianxiety Drugs and Special Problems in the Use of Psychotherapeutic Drugs 361

Kutt, H. and Louis, S. (New York): Anticonvulsant Drugs I: Patho-physiological and Pharmacological Aspects 227

Kutt, H. and Louis, S. (New York): Anticonvulsant Drugs II: Clinical Pharmacological and Therapeutic Aspects 256

Practical Therapeutics

Becke, R.F.A. (Sydney): Psoriasis: Its Nature and Treatment 85

Carden, A.B.G. (Melbourne): Management of Haemorrhoids and Associated Ano-rectal Conditions 75

Court, J.M. (Melbourne): The Management of Obesity 411

Dennerstein, G.J. (Melbourne): Vaginitis: Diagnosis and Treatment 419

Johns, M.W. (Melbourne): Management of Insomnia 290

Louis, W.J. (Melbourne): Antihypertensive Drugs in the Treatment of Hypertension 90

Mackay, J.B. (Wellington): Management of Chronic Bronchitis 81

Norris, R.M. (Auckland): Management of Acute Myocardial Infarction in General Practice 283

Therapeutic Guide
A Guide to Selection of a Systemic Antibacterial Agent 132

Drug Literature Abstracts 101, 295, 426

Subject Index 146, 312

Cumulated Subject Index Vol. 3 and 4 433